Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
7-28-2016 12:00 AM

Structural Analysis of TPR Ligand Complexes of STIP1 Implicated
in Alzheimer's Disease
Andrzej Maciejewski, The University of Western Ontario
Supervisor: Choy, Wing-Yiu, The University of Western Ontario
Joint Supervisor: Prado, Marco, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Doctor of Philosophy degree
in Biochemistry
© Andrzej Maciejewski 2016

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Biochemistry Commons

Recommended Citation
Maciejewski, Andrzej, "Structural Analysis of TPR Ligand Complexes of STIP1 Implicated in Alzheimer's
Disease" (2016). Electronic Thesis and Dissertation Repository. 3998.
https://ir.lib.uwo.ca/etd/3998

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
Amyloid-beta oligomers (AβOs) induce neurological dysfunction in part through
the cellular prion protein (PrPC) resulting in deregulation of Ca2+ homeostasis in
Alzheimer’s disease (AD). Stress inducible phosphoprotein 1 (STIP1), a cochaperone of
Hsp70 and Hsp90, protects neurons from AβO-induced cell death. As well, STIP1
interacts with the Ca2+ sensor S100A1, which is an important biomarker upregulated in
AD and regulates STIP1 and other cochaperone association with Hsp70 and Hsp90.
While the molecular details of STIP1-Hsp complexes are well studied, little information
is available concerning alternate STIP1 binding partners. Here, we investigated the
structural details of STIP1 binding to PrPC and S100A1.
We showed that residues located in a short region of PrP (90-110) mediate AβO
binding and refined the main interaction to residues 91-100. We identified that STIP1
binds to PrP through multiple domains (DP1, TPR1 and TPR2A) and that the interactions
with TPR1 and TPR2A effectively block AβO binding to PrPC and cell death. The DP1
domain interacted with the flexible N-terminal (residues 23-95), while TPR1 and TPR2A
interacts with the C-terminal (residues 90-231) of PrP. NMR spectroscopy revealed that
the TPR domains interact with PrP competitively through distinct regions, with the
TPR2A binding site overlapping with Hsp90. Our data suggest PrP, STIP1 and Hsp90
may form a ternary complex, which may influence AβO toxicity in cells.
In contrast to PrP complex formation, S100A1 binding to STIP1 is Ca2+
dependent and mediated through the TPR (TPR1, TPR2A and TPR2B) domains of
STIP1. Each TPR binds asymmetrically to a single S100A1 dimer resulting in a

i

stoichiometry of three S100A1 dimers binding a single STIP1 molecule. S100A1 bound
each TPR through a common interface spanning α-helix IV; however, with different
binding affinities. Our findings provide novel structural insights regarding STIP1
complexes with PrPC and S100A1.

Keywords
Alzheimer’s disease, neurotoxicity, cochaperone, neuronal cell death, S100A1, stressinducible phosphoprotein 1, prion protein, nuclear magnetic resonance spectroscopy,
neurodegeneration, amyloid-β
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Introduction
1.1

Protein aggregation and neurological disorders

Protein aggregation into amorphous bodies is a common mechanism shared by most
neurodegenerative diseases. Proteins that coalesce into abnormal intracellular or
extracellular fibrils and inclusion bodies within specific brain regions generally
characterize disease pathology [1]. Huntington’s disease, prion diseases, amyotrophic
lateral sclerosis (ALS), Parkinson’s and Alzheimer’s disease (AD) all involve formation
of abnormally folded proteins that accumulate as insoluble aggregates extracellularly or
in the cytoplasm.
Alzheimer’s disease is predominately a late-onset neurodegenerative disorder and the
most prevalent form of dementia. The disease typically is diagnosed in patients 65 and
older and results in a progressive loss of memory and executive function, confusion,
agitation and behavioral abnormalities. AD afflicts approximately 24 million people
worldwide and the rate of incidence is expected to increase exponentially with an aging
population [2, 3]. Alzheimer’s disease cases are segregated into 2 subtypes based on age
of onset. Early-onset AD (EOAD) patients range from 30-65 years and form the minority
of cases (1-6%), while late-onset AD (LOAD) cases are characterized in individuals 65
years old and over [3]. AD is a multi-factorial disorder with multiple genetic and
environmental factors affecting disease predisposition.
The neuropathology of AD is defined by the accumulation of two insoluble filaments;
intraneuronal neurofibrillary tangles (NFT) and extracellular amyloid plaques [4, 5].
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NFTs are composed of the hyperphosphorylated microtubule associated protein tau while
amyloid plaques are the result of accumulation and self-aggregation of the amyloid-beta
(Aβ) peptide into larger macromolecular assemblies. Tau and Aβ act separately and
interdependently to promote synaptic dysfunction and neuronal cell death [6].
The functional link between Aβ and tau was first described in in vivo mouse models
of tau and Aβ deposition. Injection of preformed Aβ fibrils into P301L mutant tau
transgenic mice, which develop a non-Alzheimer’s tauopathy, frontotemporal dementia
with parkinsonism linked to chromosome 17, resulted in a five-fold increase in NFT
accumulation at the site of injection [7]. Additionally, crosses of tauP301L mice with the
familial EOAD causative mutation (K670N/M671L) in the amyloid precursor protein
(APP) resulted in accelerated tau deposition with no change in plaque burden compared
to either parental mouse line alone [8]. These studies suggest Aβ can exacerbate NFT
formation without affecting amyloid deposition.
Numerous protein kinases have been implicated to functionally connect Aβ to tau
hyperphosphorylation at the molecular level. GSK3β, ERK1/2 and Cdk5-p25 have been
described to phosphorylate tau at Ser/Thr-Pro sites and are stimulated by Aβ treatment
[9-12]. Interestingly, recent studies suggest the non-receptor tyrosine kinase, Fyn,
hyperphosphorylates tau in response to activation by Aβ oligomer (AβO) through
molecular complexes that include the cellular prion protein (PrPC), metabotropic
glutamate 5 (mGluR5) and N-methyl-D-aspartate (NMDA) receptors [12-15]. Thus,
current models postulate Aβ accumulation upstream of tau hyperphosphorylation in AD.
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1.2

Amyloid precursor protein (APP) processing

The amyloid precursor protein (APP) is a single-pass transmembrane protein with a
large ectodomain. Eight isoforms are generated by alternative splicing though the 695
amino acid isoform is predominately expressed in the central nervous system (CNS) [16].
The major proteolytic APP pathway involves sequential cleavage of APP by α and γ
secretase complexes generating non-amyloidogenic fragments sAPPα and intracellular
fragment that are associated with synaptic plasticity and neuronal protection (Figure 1.1)
[17, 18]. Alternatively, sequential proteolytic processing by the β and γ secretases results
in a heterogeneous population of peptide variants (Aβ43, Aβ42, Aβ40, Aβ38 and Aβ37)
with various propensities to self-associate into larger amyloidogenic species [19, 20]. The
predominant peptide products are Aβ40 and Aβ42, with the former being the major
species in the normal state. In AD the ratio of Aβ42: Aβ40 increases with Aβ42
becoming the main proteolytic product [21]. Aβ42 possesses enhanced amyloidogenic
properties and the shift towards Aβ42 production is characteristic of AD. Thus, AD
results increased APP processing by the amyloidogenic pathway and failure to clear the
resultant toxic fragments [22].
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Figure 1.1. Sequential cleavage of the amyloid precurosr protein (APP).
APP is processed by two mechanisms. In the non-amyloidgenic pathway, APP is initially
cleaved by α-secretase followed by γ-secretase resulting in production of a soluble
ectodomain (APPsα) and an intracellular fragment. Amyloidgenic processing involves
sequential cleavage by β-secretase followed by γ-secretase resulting in the formation of
Aβ peptide and a soluble APPsβ fragment. Both processes generate intracellular Cterminal fragments (AICD). This figure was adapted from [22].
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In the amyloidogenic pathway, the transmembrane aspartic protease BACE1
functions as the β-secretase, initially cleaving the ectodomain of APP generating a
membrane anchored β- C-terminal fragment (β-CTF) (Figure 1.1). The γ-secretase is a
multiprotein complex composed of presenilin 1 (PS1) or presenilin 2 (PS2), nicastrin
(Nct), Aph-1 and Pen-2, which plays a functional role in the proteolytic processing of
transmembrane proteins [22]. Mutations in PS1, PS2 and APP have been linked as
causative mutations of autosomal dominant familial AD [3]. The γ-secretase cleaves the
intramembranous fragment at one of several locations in the intramembrane helix
generating the various length Aβ peptides. Aβ40 and Aβ42 are the most commonly
generated, with the latter increased in EOAD associated mutations. Aβ42 has been
classically viewed as the more toxic species and demonstrates a greater propensity for
self-association into oligomers, protofibrils, fibrils and ultimately, the characteristic
amyloid plaques seen in AD.

1.3

Amyloid-β oligomers and toxicity

While amyloid plaques are a hallmark of AD neuropathology, studies have been
unable to demonstrate a relationship between amyloid plaque load and neuronal death,
synaptotoxicity or disease severity [23]. Neuronal death is observed in regions far
removed from plaques and cases have been reported of non-demented individuals with
high plaque burden [24-26]. These studies suggest an alternative species is primarily
responsible for synaptic dysfunction in AD. The identification of small diffusible Aβ
oligomers (AβO) provides a rationale for these discrepancies. AβO are prefibrillar
intermediates which are potent neurotoxins [27]. Robust correlations are observed
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between soluble AβO concentrations and disease severity, thus the field considers soluble
AβOs as the predominant neurotoxin in AD [28, 29].
Aβ polymerization follows a complex and multifaceted pathway generating a range
of buffer-soluble oligomers (i.e. dimers, trimers, tetramers, dodecamers and high
molecular weight oligomers) during fibril formation [20]. Atomic force and electron
microscopies revealed them to be 10-15 nm spherical shaped structures [30]. AβO are
potent neurotoxins thought to trigger synaptic dysfunction, neuronal cell death and
dementia [30]. The current paradigm in AD suggests these soluble oligomeric species are
the primary pathological unit and not the amyloid plaques, which characterize the
disease.
Toxicity is thought to depend on size and aggregation state; however, due to the
diverse oligomeric and structural heterogeneity of AβOs, the toxic species and their
relative potency is poorly defined [20]. The diversity of synthetic and natural AβOs has
complicated the interpretation and reproducibility of studies [31]. SDS-stable dimers and
trimers are secreted in culture and are found in human diseased brain extracts, which
inhibit long-term potentiation (LTP) [32]. LTP is an electrophysiological mechanism
underlying learning and memory formation and is compromised in AD. Larger species
(nonamers and dodacamers) have also been observed to correlate with memory deficits in
an APP transgenic mouse model [33]. As well, larger assemblies over 100 kDa have been
found in AD brain suggesting a diverse range of sizes of AβOs are associated with
disease [34].
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Synthetic preparations of AβOs have been employed to elucidate disease
mechanisms in vitro and in an attempt to better standardize AβO preparations [35].
Synthetic AβO, also referred to as Aβ-derived diffusible ligands (ADDLs) mimic AβO
induced deficiencies including robust binding to neurons, inhibition of LTP,
synaptotoxicity and neuronal cell death [27]. Antibodies generated against synthetic
ADDLs derived oligomers cross-reacted with AD brain tissue, demonstrating synthetic
ADDL conformations are generated in vivo and are relevant in studies of AD [36].
Multiple molecular mechanisms have been implicated to contribute to AβO
toxicity. AβO association with the plasma membrane results in increased intracellular
calcium concentrations and excitotoxicity in neurons [37]. AβO have been found to
compromise the integrity of the plasma cell membrane, disrupting intracellular calcium
homeostasis [38, 39]. AβOs insert themselves into lipid bilayers leading to pore
formation or lipid bilayer defects resulting in ion deregulation [40]. Rapid increases in
intracellular Ca2+ promote further deficits, such as increases in radical formation and
oxidative stress [41]. Elevation of intracellular Ca2+ concentrations by compromising its
cellular membrane integrity may contribute to the potent neurotoxicity of AβOs and
neurodegeneration in AD.
Alternatively, binding of AβOs to the cell surface through endogenous cellular
receptors may result in aberrant signaling, synaptic dysfunction and neuronal cell death.
Indeed, a number of amyloid-protein interactions have been described between native
neuronal receptors or co-receptors/scaffold proteins resulting in detrimental effects [42].
These include α7 nicotinic acetylcholine receptor (α7nAChR), receptor for advance
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glycation end products (RAGE), ephrin type B receptor 2 and paired immunoglobulin –
like receptor B [43]. Receptors in glutamatergic transmission have garnered tremendous
interest in AβO toxicity. Glutamate is a portent neurotransmitter essential in memory
formation and synaptic plasticity [44]. In particular, the N-methyl-D-aspartate (NMDA)
receptor and metabotropic glutamate receptors (mGluR) have been demonstrated to be
susceptible to deregulation by AβO resulting in Ca2+ influx and synaptotoxicity [45, 46].
AβO were shown to depolarize neurons, disrupt glutamatergic transmission, inhibit LTP,
promote LTD and excitotoxicity [47, 48].
AβO have been demonstrated to activate NMDA receptors through the NR2B subunit
and inhibit LTP [49]. Interestingly, the cellular prion protein (PrPC) has been identified as
a coreceptor for NMDA, mGluR5 receptors and AβOs [12, 13]. AβO binding to PrPC
induces NMDA and mGluR5 activation resulting in Fyn kinase activation, thus
potentially coupling AβO toxicity to hyperphosphorylation of tau protein in AD [12, 13].

1.4

Cellular prion protein (PrPC)

The cellular prion protein (PrPC) is the pathological unit of several progressive and
fatal neurodegenerative diseases termed prion diseases. These include Creutzfeldt-Jakob
disease (CJD), kuru, fatal familial insomnia (FFI) and Gertzmann-Straussler-Scheinker
syndrome (GSS) in humans, scrapie in goats and sheep, chronic wasting disease (CWD)
in deer and elk and bovine spongiform encephalopathy (BSE) in cattle [50]. Conversion
of the normal PrPC to an alternate β-sheet and protease resistant conformer (PrPSc) is
thought to be behind the etiology of prion diseases [51, 52]. PrPSc conversion can occur
sporadically or be promoted by mutations within the PrPC gene [53]. PrPSc particles are
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transmissible, promoting conversion of endogenous PrPC to the pathogenic conformer
and initiating progressive neurodegeneration in the host.
PrPC knockout mice are resistant to prion infection while, for the most part,
maintaining normal neurological function [54, 55]. Subtle neurological phenotypes have
been identified including slight deficiencies in synaptic transmission, LTP, circadian
rhythms, spatial learning and increased susceptibility to seizures [56-58]. As well, lower
levels of anxiety and increases in locomotor activity have been observed in particular
backgrounds of PrP-null mice [59]. Ablation of PrPC was also noted to result in a chronic
demyelinating polyneuropathy [60].
PrPC is a carboxy-terminal glycophosphatidylinositol (GPI) anchored protein located
on the outer leaflet of the cellular plasma membrane (Figure 1.2) [61]. A 22 amino acid
N-terminal signaling peptide targets the nascent protein to the lumen of the endoplasmic
reticulum, where the signaling peptide is cleaved and the protein undergoes posttranslational modification [62]. The mature protein is trafficked to the cellular membrane
through the Golgi apparatus and undergoes endocytosis and cycling from the cell
membrane and intracellular compartment. Pulse-chase experiments indicate the half-life
of PrPC is about 1.5-2 hrs, demonstrating the protein undergoes rapid recycling [63].
Internalization of PrPC is dependant on the N-terminal region of PrPC and the initial basic
cluster ‘KKRPK’ [64, 65].
Mature PrPC contains flexible disordered N-terminal spanning residues 23-124 and a
structurally conserved globular C-terminal (Figure 1.2) [66, 67]. The disordered Nterminal encodes two regions of high conservation termed the octapeptide region (OR)
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and a region rich in hydrophobic amino acid content spanning 22-90 and 111-134,
respectively. The OR encodes four to five octameric repeats possessing a high affinity for
divalent transition metals (Cu2+, Ni2+, Zn2+ and Mn2+) [68].
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Figure 1.2. Structure of cellular prion protein (PrPC).
PrPC is composed of a disordered N-terminal and a C-terminal globular domain rich in αhelical content. The protein is tethered to the extracellular face of the plasma membrane
by glycophosphatidylinositol (GPI) anchor. (PDB: 1AG2) [66].
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The globular C-terminal presents a highly α-helical fold composed of three helices
(residues 145-151, 173-188 and 200-229) and a short a β-sheet formed by residues 128131 and 161-164 [66, 67]. A single disulfide bond connects α-helices 2 and 3,
significantly contributing to PrPC stability [69]. PrPC is subject to glycosylation at N181
and N197 positions in human PrPC (N180 and N196 in mouse) and has been isolated in
the unglycosylated, mono- or di-glycosylated forms [70]. Different glycosylation states
have been reported to be differentially distributed through the central nervous system and
other tissues [71-73]. High-resolution structural studies by solution nuclear magnetic
resonance (NMR) spectroscopy and X-ray crystallography have revealed a high degree of
inter-species structural homology [67, 74, 75].
The prion protein is ubiquitously expressed in adult tissues and highly enriched
within cholesterol-rich lipid rafts of neuronal postsynaptic membranes in the central
nervous system (CNS) [76]. As well, high expression has been noted in elements of the
immune system, hematopoietic stem cells (HSCs), blood and lymphoid organs [77].
PrPC is a scaffold protein that modulates cellular signaling at the cellular membrane
through protein-protein interactions with various cellular ligands [76]. These include a
diverse set of ligands including laminin, heparin sulfate, casein kinase 2 (CK2) and 14-3-3
[78-81]. Protein-protein interactions have been mapped throughout the extent of the
protein; however, large numbers of PrPC binding partners interact through the disordered
N-terminal region, presumably due to its increased accessibility on the plasma membrane
compared to its C-terminal GPI-anchored globular domain.
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PrPC has been identified as a high affinity receptor for soluble AβO, in an
unbiased screen of a cDNA library expressed in COS-7 cells [82]. PrPC associates with
AβOs with sub-nanomolar affinity through residues 23-27 and 95-110 of the N-terminal
of PrPC [82-84]. Immuno-staining of neuronal cultures following AβO results in
characteristic punctate staining on the neuronal surface [82]. AβO staining can be
significantly reduced by pretreatment with anti-PrPC antibodies or RNA silencing of
PrPC; however these strategies do not eliminate AβO binding suggesting AβO retains the
capacity to bind neuronal cells through alternate mechanisms such as other identified
binding partners [82, 85].
Association of PrPC or the disordered N-terminal containing these binding sites
inhibited the oligomerization and fibrillization of AβO in vitro [86, 87]. Alternatively,
PrPC disassembled mature fibrils into smaller AβO species, potentially stimulating
formation of neurotoxic species [88]. Thus, binding of AβO to PrPC may influence the
kinetics of Aβ oligomerization and the toxicity of the generated Aβ species; however, the
implications of these observation on neurotoxicity are currently unknown.
PrPC is required for cell death in vitro, epileptiform discharges, synapse loss,
serotonin axon degeneration and cognitive and memory deficits associated with AβO [82,
89-91]. Association of AβO or AD brain extracts resulted in the inhibition of LTP in CA1
hippocampal slices in a PrPC dependent manner [82].
PrPC directly interacts with mGluR5 [92, 93]. Synthetic AβO or AβO isolated
from AD disease brain resulted in PrPC-dependent activation of Fyn kinase [12]. AβOPrPC engagement resulted in increased intracellular Ca2+ levels, eEF2 phosphorylation,
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reduction in global transcription, and dendritic spine loss. PrPC- AβO complex formation
also disrupts NMDA receptor activity resulting in a biphasic transient increase in Ca2+
and NMDA receptor surface expression [13].
Initially, binding of AβO to PrPC resulted in Fyn activation, NR2B subunit
phosphorylation, and increased NMDA receptor trafficking to the cell surface. This
increase is coupled to increased intracellular Ca2+ resulting in excitoxicity followed by
dendritic spine loss. Following 60 minutes of AβO treatment, NMDA receptor surface
expression is reduced, desensitizing neuronal cells and resulting in the attenuation of the
Ca2+ currents.
The cytotoxic stresses induced by PrPC- AβO complexes have made the interaction an
appealing target for therapeutic intervention. Disruption of AβO-PrPC complexes using
monoclonal antibodies directed against the PrPC -AβO binding site (residues 95-110) or
α-helix 1 demonstrated the greatest efficacy, either by directly blocking the binding site
or occluding it by steric hindrance [82, 84, 94]. This inhibition translated to inhibition of
AβO-induced deficits. Thus, modulation of PrPC- AβO complex may be of therapeutic
value in AD. Interestingly, the PrPC ligand, stress-inducible phosphoprotein 1 (STIP1)
inhibits AβO binding and toxicity implicating the pathway as an endogenous protective
mechanism against Aβ toxicity [95].
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1.5

Hsp70 and Hsp90 chaperones

Proper protein folding in the cell is facilitated through a large and diverse class of
chaperones termed heat shock proteins (Hsp). Hsp90 is one of the best conserved Hsps
and accounts for 1-2% of total protein in the cell [96]. Hsp90 activity is regulated through
interactions with a large network of cochaperones to fold a wide range of client proteins
that include a number of oncogenic protein kinases and steroid receptors. Initially, client
proteins are recruited by Hsp40 and Hsp70 and are transferred to Hsp90 by stressinducible phosphoprotein 1 (STIP1) [97]. Finally, an additional co-chaperone p23 is
recruited and ATP hydrolysis results in structural rearrangements in Hsp90 that promote
client maturation and dissociation of the complex [97]. Recent studies suggest Hsp90 has
an important role in neurodegeneration. Hsp90 stabilizes toxic aggregates such as Aβ and
phosphorylated tau [98]. Pharmacological inhibition of Hsp90 results in Hsp70 and
Hsp40 upregulation, which is thought to channel aberrant folded species for degradation
[98].

1.6

Stress-inducible phosphoprotein 1 (STIP1)

Stress-inducible phosphoprotein 1 (STIP1) is a cellular cochaperone that coordinates
Hsp70 and Hsp90 activity during client protein folding [99, 100]. STIP1 expression is
upregulated during cellular stress in yeast [101]. STIP1 is a modular protein composed of
three tetratricopeptide repeat domains (TPR1, TPR2A and TPR2B) and two domains rich
in aspartate and proline residues (DP1 and DP2) (Figure 1.3). Tetratricopeptide repeat
domains are composed of repeating units of 34 amino acid degenerate sequences that
form two anti-parallel α-helices joined by a short flexible linker [102]. Multiple TPR
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motifs are arranged in tandem forming an amphipathic groove, which serves as the
binding site for protein-protein interactions [103].
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Figure 1.3. Structural schematic of stress-inducible phosphoprotein 1 (STIP1).
Individual domain boundaries are highlighted with their corresponding structures
depicted below: TPR1 (PDB: 1ELW), DP1 (residues 1138-190 (2LLV), TPR2A-TPR2B
(PDB: 3UQ3) and DP2 (PDB: 2LLW) [103, 104].

18

The TPR domains of STIP1 bind Hsp70 and Hsp90 to facilitate client protein
folding. The amphipathic groove of each TPR domain binds the C-terminal ‘EEVD’
motifs of Hsp70 and Hsp90, anchoring them to the protein [103]. Specificity is achieved
through amino acid contacts directly N-terminal of the ‘EEVD’ motifs of each Hsp. This
interaction is predominately mediated through conserved electrostatic interactions
forming a two-carboxylate clamp with the Asp residue in each Hsp70 and Hsp90 peptide.
While the C-terminal Hsp interactions are critical for TPR and Hsp90 binding, additional
contacts are made with the middle domain of Hsp90 [104, 105].
Binding of Hsp90 by STIP1 results in non-competitive inhibition of its ATPase
activity through interaction with TPR2A-TPR2B fragment and stabilizes an open
conformation in Hsp90; however, the human homologue appears to be an approximately
10-fold less potent inhibitor [106, 107]. Hsp engagement is facilitated through sequential
interactions with the individual TPR domains of STIP1 [108]. The function of the DP
domains (DP1 and DP2) is less clear. Currently, no protein ligands have been identified
for the DP domains of STIP1. Recently, the solution NMR structures of the yeast DP1
and DP2 domains were solved revealing a novel α-helical protein fold encoding six and
five α-helices, respectively [104]. DP1 contains an additional α-helix that is believed to
stabilize the arrangement of secondary structural elements and occupies a slightly
positive groove. This groove is accessible in DP2 and may serve as a potential binding
site for as of yet unidentified ligands. The minimal fragment of STIP1 that supports client
activation is composed of TPR2A-TPR2B-DP2 C-terminal of STIP1 [104, 109]. As well,
the C. elegans STIP1 homologue only encodes this fragment which suggest the TPR1DP1 module may be dispensable for client activation in vivo [110].
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Interestingly, constructs lacking the DP2 domain did not support glucocorticoid
receptor activation in yeast cells [104]. X-ray crystallographic structures of the TPR2ATPR2B domain revealed the linker between these domains is quite rigid. This results in
the TPR domains adopting an S-shaped form with their hydrophobic clefts responsible
for binding the C-terminal Hsp residues oriented in opposite directions [104].
Complementary NMR spectroscopy experiments revealed additional inter-domain
contacts are formed between the C-terminal helix of TPR2B, the linker connecting
TPR2B to the DP2 domain and α-helices 1 and 2 of the DP2 domain. These additional
contacts form a rigid C-terminus composed of TPR2A-TPR2B-DP2. These results
indicate DP2 contributes to the quaternary structure of STIP1 and rationalizes its
importance in STIP1 function.
STIP1 possesses two Hsp70 binding sites located in TPR1 and TPR2B; however,
it binds to Hsp70 in a 1:1 stoichiometry [103, 108]. The current model for STIP1 function
in Hsp70 and Hsp90 coordination speculates that in the absence of Hsp90, the TPR2B
domain represents the high-affinity binding site for Hsp70. Hsp90 binding induces a
more ‘open’ conformation between TPR1-DP1 fragment and the functional C-terminal
TPR2A-TPR2B-DP2 domains. Hsp90 binding to TPR2A reduces accessibility of Hsp70
binding to TPR2B, thus the TPR1 domain becomes the predominant binding site for
Hsp70 in the ternary complex [108]. Binding of Hsp90 has been observed to affect the
dynamics of STIP1, reorienting the TPR1-DP1 module into close proximity to TPR2B,
presumably facilitating transfer of Hsp70. Thus, the length of the linker bridging TPR1DP1 to TPR2A-TPR2B-DP2 impacts STIP1 function in client refolding. Deletion of the
linker results in decreased formation of ternary complexes of STIP1-Hsp70-Hsp90 and
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decreased protein client activation in vivo [108]. Interestingly, this linker is
approximately 30 residues shorter in higher order eukaryotes. Thus, differences in
dynamics of STIP1-Hsp70-Hsp90 ternary complexes may exist in higher order
eukaryotes affecting client protein activation [108].
STIP1 is subject to posttranslational modification, which regulates its
cochaperone activity [109]. Five different phosphorylation sites have been identified in
human STIP1 homologue corresponding to S16, S189, T198, Y354 and S481.
Phosphomimetic mutations resulted in decreased glucocorticoid receptor activation in
vivo and Hsp70 binding affinities indicating phosphorylation regulates STIP1’s cochaperone function [109]. Interestingly, Y354E phosphomimetic variant located in the
loop joining TPR2A-TPR2B, appeared to disrupt the rigid linker joining the two domains
and promotes a more dynamic flexibility and leads to a loss of function [109].
Additionally, STIP1 is subject to SUMOylation by PIAS1 whose binding results in its
nuclear accumulation [111].
Hsp70 and Hsp90 overexpression is a common phenotype of human cancers and
correlates with a poor prognosis [112]. Pharmacological inhibition of the Hsp machinery
has become a popular target in cancer treatment [113]. Recent studies have explored
inhibition of STIP1 cochaperone function as an alternate strategy in destabilizing Hsp90
oncogenic ligand folding [114, 115]. Studies have demonstrated that STIP1 promotes
proliferation and migration in glioblastoma and pancreatic cancer cell lines [116, 117].
Down-regulation of STIP1 by RNAi resulted in decreased pancreatic cell line
invasiveness and down-regulation of numerous oncogenic Hsp90 client proteins [116].

21

Inhibition of Hsp90 interaction with the TPR2A domain of STIP1 using a novel hybrid
TPR peptide has demonstrated selective cancer-cell cytotoxicity [118].
Selective inhibition of the Hsp machinery has also garnered interest in
neurodegenerative diseases owing to their roles in regulating proper protein folding.
Inhibition of Hsp90 results in upregulation of Hsp70 and Hsp40 through transcriptional
activation of the transcription factor heat-shock factor 1 (HSF-1). Hsp40 and Hsp70
overexpression are thought to promote protein disaggregation and degradation [119].
Hsp90 is believed to stabilize aberrantly folded proteins, thus inhibition of the chaperone
and co-chaperone activity at particular nodes may be of therapeutic value in protein
aggregation disorders [120].

1.7

STIP1 as a signaling molecule

In addition to STIP1’s well-documented role as an Hsp cochaperone, STIP1 also
functions as a neurotrophic and neuroprotective signaling molecule through PrPC [121124]. STIP1 is actively secreted by a non-canonical pathway through extracellular
vesicles (EVs) [125]. Upon cellular stress, such as irradiation or ischemia, astrocyte
STIP1 secretion is enhanced promoting cell survival through PrPC-dependent pathways
[121, 122]. The hydrophobic core of PrPC (residues 113-128) has been determined to
engage in complex formation with the TPR2A (residues 230-245) of STIP1. Complex
formation promotes perturbation of PrP α-helix (143-153) of the globular C-terminal of
PrPC and compaction of STIP1 structure in PrPC-STIP1 complex [126]. These structural
remodeling events may recruit additional protein interactions and is consistent with PrPC
function as a scaffold protein-modulating cell signaling events.
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PrPC- STIP1 engagement results in an increase in intracellular Ca2+ concentration
through the α7 nicotinic acetylcholine receptor (α7nAChR) (Figure 1.4) [127]. Signaling
induces neuroprotection and neuroproliferative signaling through PKA and ERK1/2
pathways, with the latter requiring internalization of PrPC [128]. α7nAChR expression is
altered in AD models and the receptor itself has been identified as an AβO receptor
[129]. Inhibitors against AβO binding to α7nAChR show beneficial effects in AD
models, suggesting modulation of this pathway may play an important in AD [130].
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Figure 1.4. STIP1 signaling pathway through PrPC at the cellular membrane.
STIP1 binding to the N-terminal flexible tail of PrPC results in intracellular Ca2+ influx
from the outside environment through the α7nAChR. The resulting cascade leads to PKA
and ERK activation, which promote cell survival and differentiation, respectively.
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In addition, STIP1 signaling through PrPC enhances neuronal protein synthesis
through PI3K-Akt-mTOR activation and phosphorylation of eIF4E-binding proteins (4EBPs), which release eIF4E initiation factor, promoting translation initiation [131].
Regulation of protein synthesis by extracellular signaling molecules is involved in critical
pathways in neuronal development and synaptic plasticity in the nervous system [132].
Stimulation of neuronal protein synthesis is corrupted by scrapie prion (PrPSc) infection,
thus loss-of function of this pathway may contribute to the neurodegeneration seen in
prion diseases [131].
Deletion of STIP1 in mouse models is embryonic lethal by E 10.5 and embryos
presented malformed neural tube and limb buds due to increased levels of apoptotic cell
death [122]. Maternal extraembryonic STIP1 protein, possibly transferred, from placental
disruption is sufficient for initial blastocyst (E 3.5) implantation and survival; however, is
not present in E10.5 embryos. Embryonic fibroblasts from STIP1 deficient embryos
present increased DNA damage marker γ-H2AX [122]. Enhanced cellular stress induces
STIP1 translocation and accumulation of STIP1 in the nucleus [133]. Nuclear localization
is regulated by phosphorylation at S189 and T198 located in the linker joining TPR1-DP1
to the C-terminal of STIP1 and adjacent to the functional NLS (residues 222-239) [134].
As well, interaction of STIP1 with the E3 SUMO ligase PIAS1 results in STIP1
accumulation after genotoxic stress following irradiation [111]. Thus, STIP1 nuclear
accumulation is influenced by cellular stress and by protein posttranslational
modifications and ligand interactions.
A growing body of evidence has revealed alternate functions of STIP1 unrelated to its
regulation of Hsp70/Hsp90 activity. Importantly, extracellular STIP1 is a potent
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neuroprotective signaling molecule through PrPC [95, 124, 127, 128]. STIP1 can directly
inhibit AβO binding to PrPC in vitro by physically occluding the AβO site and
neuroprotective signal transmission through α7nAChR, which translated to rescue of
AβO induced toxicity [95]. A thorough molecular understanding of the PrPC-STIP1
interaction may provide insight into cellular mechanisms involved in the early stages of
disease and potential therapeutic strategies in AD.

1.8

S100A1

Disruption of calcium homeostasis is implicated in numerous and diverse human
diseases including heart disease and several neurological disorders [135]. Calcium
signaling mechanisms are tissue and cell specific, temporarily regulated and undergoing
continuous remodeling. Diverse signaling cascades promote mobilization of intracellular
or extracellular stores through numerous Ca2+ channels, pumps and exchangers [136].
Deregulation of calcium signaling resulting in disruption of membrane conductance has
long been associated with AD pathology, preceding deposition of Aβ plaque deposition
and inflammation that define AD pathology [137-139]. Intracellular AβO have been
demonstrated to induce Ca2+ flux by directly permeabilizing the membrane or through
activation receptor signaling complexes and Ca2+ channels [39, 49, 140]. Fluctuations in
Ca2+ influence synaptic plasticity and processes such LTP and long term depression
(LTD) and thus AβO can disrupt learning and memory in AD.
Ca2+ also functions as an important cofactor in a large set of calcium sensor proteins,
modifying protein-protein interactions and influencing downstream events. The S100 –
family of proteins is a well-studied family of calcium sensor proteins encompassing
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approximately 20 member proteins [141]. S100-family function as modulators in calcium
signaling. Expression of these proteins is cell type and tissue specific and their
differential expression has been implicated in a diverse range of diseases, including
psoriasis, rheumatoid arthritis, cardiomyopathy, multiple sclerosis, Down’s Syndrome,
Alzheimer’s disease and several forms of cancer [142-145]. Thus, many S100 proteins
serve as diagnostic biomarkers in disease.
S100 proteins are homo or hetero dimeric proteins of the EF-hand superfamily. Each
subunit is composed of two helix-loop-helix EF-hand motifs (residues 19-32 and 62-73 in
S100A1), which coordinate four calcium ions [146-148] (Figure 1.5). In the apo-state αhelices III lie nearly perpendicular to α-helices IV, burying a large hydrophobic pocket
that serves as the binding site for many S100 ligands [148]. Upon calcium binding, αhelix III of each subunit undergoes a large conformational reorientation of approximately
100° exposing the hydrophobic face of α-helices IV, which along with residues of αhelices III and the interconnecting hinge region, serve as the predominant ligand binding
site in Ca2+ dependant protein-protein interactions (Figure 1.5) [149].
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Figure 1.5. Ribbon diagram of apo-S100A1 (left) (PDB: 1K2H) and Ca2+-bound
S100A1 (right) (PDB: 1ZFS).
Ca2+ induces a conformational change, which reorients α-helices III of each protomer
exposes a hydrophobic region in α-helices IV. The α-helices of a single protomer are
labeled [146].
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S100A1 was one of the first family members discovered and originally isolated
from bovine brain tissue [150]. The protein is abundantly expressed in heart, skeletal
muscle and brain tissues [151]. S100A1 expression has been implicated in multiple and
diverse human diseases including specific types of cancer, heart failure and neurological
diseases, importantly AD. S100A1 is found in the hippocampus, cerebral cortex and
amygdala [152]. The protein is found both in intracellular compartments as well as in the
extracellular space where it interacts with several cell surface receptors [151, 153].
S100A1 has been found to regulate APP processing, tau phosphorylation and Aβ
oligomer induced neuronal cell death. Knockout of S100A1 in AD mouse models
resulted in decreased hippocampal inflammation, and decreased Aβ amyloid plaque
burden [144, 154]. As well, numerous S100A1 ligands have been implicated in AD such
as the receptor for advanced glycation end products (RAGE) and ryanodine receptors
[154] [155].
Recent studies have implicated S100A1’s role in the regulation of co-chaperone
interactions with Hsp70/Hsp90 chaperone machinery [156]. These co-chaperones include
protein phosphatase 5 (PP5), FK506-binding protein (FKBP52), cyclophilin 40 (Cyp40)
and STIP1 [156] [157]. S100A1 inhibited their association through binding each ligand’s
respective TPR domains, which are commonly used by co-chaperones to interface with
the conserved C-terminal ‘EEVD’ motifs found in Hsp70 and Hsp90. Therefore, S100A1
may regulate Hsp activity during client protein refolding through regulation of cochaperone complexes.
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1.9

Scope of thesis

STIP1 is a multifaceted protein molecule that functions as a cellular cochaperone,
regulating Hsp70 and Hsp90 activity and client maturation. STIP1 binding to S100A1
protein has been suggested to influence its interactions with Hsps. Additionally,
extracellular STIP1 acts as a potent neuroprotective and neurotrophic signaling molecule
through PrPC. Therefore, molecular understanding of STIP1 ligand interactions has
implications in numerous cellular diseases including cancer and neurodegeneration.
In order to ascertain the structural details of STIP1 ligand complexes, extensive NMR
characterization of STIP1 was undertaken. 1H-15N HSQC spectra revealed the protein
was too large to acquire adequate information on STIP1 complexes, thus the individual
TPR (TPR1, TPR2A and TPR2B) and DP (DP1 and DP2) domains were cloned and
studied individually (chapter 2). NMR backbone assignments were completed and
confirmed to agree with the currently available literature. These NMR assignments
provide the foundation for the study of STIP1-ligand complexes. As well, the impact of a
wide range of conditions on the stability of the previously identified ligand binding
domains of STIP1, the TPR domains, was assessed.
The modular structure of STIP1 and structural similarity of the TPR domains lead us
to explore the potential of alternate binding sites of PrPC than previously reported. We
discovered that in addition to the TPR2A domain, the TPR1 and DP1 domains bound
PrP. DP1 bound the flexible N-terminal of PrPC, while the TPR domains bound
competitively to PrP (90-231). In addition, the AβO binding site on PrP was refined to
residues 90-110. The TPR1 and TPR2A domains could inhibit AβO to PrPC in vitro and
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in primary neuronal mouse cultures. Importantly, this inhibition translated to reduced
neuronal cell death.
Finally, the molecular details of the recently identified and poorly understood STIP1S100A1 complex was investigated. Both proteins are secreted and S100A1 is a marker
for neuronal stress and injury [125, 142]. S100A1 may regulate STIP1 interactions in the
extracellular and intracellular environment. The stoichiometry of binding was determined
to be 3 S100A1 dimers per STIP1 molecule. Each TPR domain of STIP1 participated in
binding to each S100A1 dimer; however, with significantly different binding affinities
determined by isothermal titration calorimetry (ITC). NMR was used to define the
binding interfaces for S100A1 and individual TPR domains. The binding interface for
each TPR domain on S100A1 was determined to encompass a large hydrophobic groove
spanning α-helix III of S100A1 and was shared amongst each TPR domain. These results
suggested differences in binding were due to the amino acid composition of each TPR.
Due to spectral broadening, the binding site on each TPR could not be identified with
great confidence and alternate strategies for obtaining the S100A1 binding site on TPR
domains are discussed.
The work presented in this thesis has advanced our understanding of molecular
complexes of STIP1 involved in AD. The structural details of interaction between STIP1
and PrP were explored and novel regions were identified to mediate binding and inhibit
AβO toxicity in neuronal cultures. As well, the molecular details of the poorly
understood STIP1-S100A1 complex were defined. These results provide structural details
and provide the foundation for future studies of STIP1 ligand complexes beyond the
traditionally studied co-chaperone activity with Hsp proteins.
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2

Structural characterization of STIP1 domains

2.1 Introduction
Proper folding of nascent peptides by molecular chaperones is a fundamental
process of life. Heat-shock proteins (Hsp)70 and Hsp90 are evolutionary conserved
chaperones which mediate folding of key cellular client proteins involved in proliferation,
differentiation and apoptosis [1, 2] . Hsp90 targets include numerous oncogenic proteins
implicated in tumor growth and survival including steroid hormone receptors and protooncogenic kinases such as Akt [3], Raf-1 [4] and Her2/neu [5]. Hsp90 over-expression
correlates with tumor invasiveness and poor prognosis, thus pharmacological inhibition
of the chaperone response has become an alluring target for therapeutic intervention in
multiple cancer models [6].
Client maturation is facilitated by a number of co-chaperone proteins that regulate
Hsp70 and Hsp90 activity. Hop/STIP1 (Hsp-organizing protein/stress-inducedphosphoprotein 1) is a key scaffold protein, which coordinates client transfer from Hsp70
to Hsp90 in the later stages of client maturation [7, 8]. Initially, client proteins complex
with Hsp40 and Hsp70 [9, 10]. Hop/STIP1 initiation promotes client transfer from Hsp70
to Hsp90 by simultaneously binding the two chaperones through distinct tetratricopeptide
repeat (TPR) domains [11].
Hop/STIP1 is a modular protein composed of three structurally related TPR
domains (TPR1, TPR2A and TPR2B) and two aspartate-proline rich regions (DP1 and
DP2) [12]. TPR domains are composed of multiple degenerate 34 amino acid repeats
forming anti-parallel helix-turn-helix motifs. These serve as protein-protein interaction
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modules in multi-protein complexes [13]. Hsp coordination by TPR domains is
accomplished through the conserved C-terminal residue ‘EEVD’ motifs of Hsp70 and
Hsp90. X-ray crystallographic data of human and yeast TPR domain complexes with
Hsp70 and Hsp90 C-terminal peptides indicate specificity is determined by hydrophobic
contacts directly N-terminal of the ‘EEVD’ motif [11]; however, additional extensive yet
poorly understood contacts are formed between STIP1 and Hsps, stabilizing the
interaction [14]. The TPR1 and TPR2B domains facilitate Hsp70 binding, while TPR2A
is the primary Hsp90 binding site [15]. During client maturation Hsp70 is initially
recruited to the TPR1 domain of STIP1. Upon Hsp90 binding, Hsp70 is transferred to the
TPR2B domain to facilitate client transfer from Hsp70 to Hsp90 [15].
The functional roles of the DP domains of STIP1 are more enigmatic. The TPR1
and DP1 domains are dispensable for client protein maturation, with the minimal
functional fragment comprising of TPR2A-TPR2B-DP2 [14]. Inter-domain contacts have
been identified between the DP2 and TPR2A-TPR2B domains of yeast STIP1, while the
DP1 domain is thought to function as a flexible linker facilitating transfer of Hsp70 from
the TPR1 to the TPR2B domains [15].
Studies have demonstrated that STIP1 promotes proliferation and migration in
glioblastoma and pancreatic cancer cell lines [16, 17]. Down-regulation of STIP1 by
RNAi resulted in decreased pancreatic cell line invasiveness and down-regulation of
numerous oncogenic Hsp90 client proteins [17]. Inhibition of Hsp90 interaction with the
TPR2A domain of STIP1 using a novel hybrid TPR peptide has demonstrated selective
cancer-cell cytotoxicity [18]. Thus, inhibition of STIP1 binding to Hsp machinery has
been suggested as an alternative approach in novel cancer therapeutics [19, 20].
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Secreted STIP1 also functions as a cell-signaling molecule promoting
neuritogenesis and neuroprotection in hippocampal neurons through its interaction with
the cellular prion protein (PrPC) [21-24]. The PrPC binding site of STIP1 has been
localized to the N-terminal of STIP1, with TPR1, DP1 and TPR2A domains of STIP1
contributing to complex formation (See Chapter 3). Recently, neuroprotective signaling
induced by PrPC-STIP1 complex formation rescued primary mouse hippocampal neurons
suggesting PrPC-STI1 may play a role in the progression of Alzheimer’s disease [25].
Nuclear magnetic resonance (NMR) spectroscopy has been proven to be a robust
technique in the study of macromolecular complexes. NMR provides detailed structural
information on a per residue basis to unambiguously identify regions of macromolecules
which interact or undergo conformational changes upon complex formation [26]. The 1H15

N HSQC (Heteronuclear Single Quantum Correlation) spectra contain a single peak

corresponding to each amino acid in a protein (except proline residues which lack amide
protons) and serve as a “finger-print” of a protein [26, 27]. Upon, titration of a binding
ligand, residues involved in complex formation or undergoing a conformational change
(i.e. change in their chemical environment) demonstrates perturbations in their peak
resonances and allows to identify the protein-ligand interfaces at the structural level.
For this approach to be effective, the identity of each peak in the 1H-15N HSQC
spectra must be correlated to a particular residue in the protein sequence. This requires a
series of experiments to assign the individual backbone amides to particular peaks in the
spectra. Backbone resonance assignment of the individual domains of STIP1 domains
and characterization of the TPR domains will provide the foundation for the study of
STIP1 protein-protein interactions, as well as provide the structural basis for the
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screening of selective inhibitors of Hsp complex formation that may prove as effective
cancer treatments and for future studies involving the STIP1-PrPC signaling complex and
other ligand interactions.

2.2
2.2.1

Materials and Methods
Protein expression and purification

The expression vectors containing mouse full-length STIP1 and the individual
domains (TPR1 (residues 1-118), DP1 (residues 119-216), TPR2A (residues 217-352),
TPR2B (residues 353-480) and DP2 (residues 481-542)) were transformed in E. coli
BL21 (DE3) pLysS. For backbone amide resonance assignment of each STIP1 domain
(TPR1, DP1, TPR2A, TPR2B and DP2), uniformly 15N, 13C- labeled protein was overexpressed by growing E. coli in 1 L M9 media supplemented with 1 g of 15NH4Cl and 3 g
of 13C-glucose at 37°C to an OD600 of 0.9, at which point protein over-expression was
induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). For all other
experiments, the protein was grown in M9 minimal media without isotopically labeling
the protein. Cultures were grown overnight at 22°C and centrifuged pellets were frozen
for storage. N-terminally His-tagged fusion proteins were purified by affinity
chromatography using Ni SepharoseTM 6 Fast Flow beads (Amersham Biosciences). The
N-terminal His-tag was removed by incubation with His-tagged Tobacco Etch Virus
(TEV) protease overnight at 22 °C and proteins were analyzed by SDS-PAGE. TEV
protease was removed by an additional Ni2+ affinity chromatography step. Proteins were
dialyzed into the appropriate buffers for further experimentation as noted.
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2.2.2

Circular dichroism (CD) Spectropolarimetry
CD spectra were acquired on a Jasco J-810 spectropolarimeter (Easton, MD).

Spectra of TPR1 and TPR2A at approximately 0.1 mg/mL concentrations were collected
in 10 mM sodium acetate, pH 5 or 50 mM sodium phosphate pH 7 or 8 buffers
supplemented with 1mM DTT at 20°C. Five accumulated scans were used for each
spectrum. Thermal denaturation was conducted over a temperature range consisting of
10°C to 95°C. The spectra were deconvoluted using the CDSSTR analysis program from
the DichroWeb (http://dichroweb.cryst.bbk.ac.uk) online analysis software package using
the SMP180 (optimized for 190-240 nm) reference set [28, 29].

2.2.3

Analytical Ultracentrifugation – Sedimentation Equilibrium
and Gel Filtration Chromatography
Analytical ultracentrifugation (AUC) experiments were performed at 20 °C in 50

mM sodium phosphate, 50 mM NaCl, 1 mM DTT, pH 7.0 on TPR2A (50 µM) using a
Beckman Optima XL-A Analytical Ultracentrifuge equipped with an An60Ti rotor
containing six-channel Epon-charcoal centerpieces and 1.2 cm path length.
(Biomolecular Interactions and Conformations Facility, University of Western Ontario).
Absorbance measurements were collected at 290 nm in 0.002 cm radial steps and
averaged over 10 scans. Sedimentation equilibrium measurements were collected at rotor
speeds of 16 000, 20 000, 24 000 and 28 000 rpm. Data was fit to the following global
single-ideal species model equation using GraphPad Prism
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(Equation 1) where C is the concentration of protein at radius x, C0 is the concentration at
initial radius x0, ω is the angular velocity, vbar is the partial specific volume of the protein,

ρ is the solvent density, R is the ideal gas constant, T is the absolute temperature, I0 is the
baseline offset and Mobs is the fit of the molecular weight based on sedimentation data.
Analytical gel filtration of TPR2A was carried out on a Superdex 75 gel filtration
column (Amersham Biosciences) in 50 mM sodium phosphate, 50 mM NaCl, 1mM DTT,
pH 7 at a flow rate of 0.5 mL/min. The elution profile was compared to the following
globular protein standards of known molecular weight: 67 kDa, 43 kDa, 23 kDa, 13.7
kDa.

2.2.4

Backbone amide NMR Resonance Assignments
STIP1 domains (TPR1, DP1, TPR2A, TPR2B, DP2) were dialyzed into 50 mM

sodium phosphate buffer, 50 mM NaCl, 1mM DTT at pH 7 and subsequently
concentrated to ~ 500 µM. NMR samples contained 10 % D2O and 100 µM 2,2dimethyl-2-sila-pentane-5-sulfonic acid (DSS) for 1H and 13C chemical shift referencing.
NMR experiments for backbone resonance assignments of each domain were conducted
at 25°C on a Varian INOVA 600 MHz spectrometer equipped with either a cryogenic
probe or a regular triple resonance probe (UWO Biomolecular NMR Facility). Sequential
assignments were obtained for each domain using the following Biopack experiments:
TPR1 (HNCACB, CBCA(CO)NH and C(CO)NH), DP1(HNCACB, CBCA(CO)NH and
C(CO)NH), TPR2A (HNCACB and CBCA(CO)NH), TPR2B (HNCACB and
CBCA(CO)NH) and DP2 (HNCACB, CBCA(CO)NH). All spectra were processed using
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NMRPipe and analyzed using CARA [30]. NMR spectral images were presented using
NMRViewJ or SPARKY [31-33].
Chemical shift assignments have been deposited in the BioMagResBank
(http://www.bmrb.wisc.edu), under accession numbers 18691 and 18689 for the TPR1
and TPR2A domains, respectively.

2.2.5

HSP90 chemical shift mapping
Binding of the TPR2A domain to the peptide encoding the C-terminal Hsp90

residues (Ac-MEEVD-NH2) (GenScript Inc. USA) was confirmed by 1H-15N HSQC
spectra collected in the presence and absence of equimolar concentrations of Hsp90
peptide (~250 µM). Experiments were collected on a Varian INOVA 600 MHz
spectrometer equipped with a cryogenic probe (UWO Biomolecular NMR Facility).
The magnitude of chemical shift perturbations for traceable residues was
calculated from the combined chemical shift changes in 1H and 15N dimensions (Δω =
|0.2 * Δ15N| + |Δ1HN|) in ppm. The resultant chemical shift changes were mapped on to
the crystal structure of TPR2A (PDB: 1ELR) and presented using UCSF Chimera
Molecular Modeling System [11, 34].

2.3
2.3.1

Results
Structural analysis of STIP1

The relative large molecular weight of STIP1 (63 kDa) and multi-domain
assembly raised the question if detailed structural studies by NMR were feasible. Fulllength STIP1 was successfully purified from the soluble fractions in E. coli BL21
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(pLysS) (Figure 2.1B) TEV incubation led to successful removal of the poly-histidine tag
and purification of soluble STIP1 of high purity (>95%). 1H-15N NMR HSQC spectra of
full-length STIP1 contained a small subset of the backbone amide resonances
(approximately 150 peaks) expected for a protein of this size (543 residues) (Figure 2.1B)
STIP1 appeared to be of the correct molecular weight when analyzed by SDS-PAGE
indicating the lack of amide resonances is not the result of protein degradation (Figure
2.1C). The majority of the resonances which are resolved cluster in a narrow region in the
HSQC spectrum, spanning ~1 ppm. The narrow spectral width of these resonances
signifies they likely represent flexible loop-regions or inter-domain linkers of STIP1. The
absence of signals from the folded functional domains of STIP1 is likely due to its large
molecular size and elongated structure resulting in enhanced relaxation and peak
broadening.
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Figure 2.1. 1H-15N HSQC of full-length STIP1 indicates NMR spectroscopy of fulllength protein is unfeasible due to lack of backbone amide resonances.
(A) 1H-15N HSQC spectra of full-length STIP1. (B) SDS-PAGE of purified STIP1. (lane
1) Soluble bacterial lysate of E. coli over-expressing STIP1. (lane 2) Ni2+
chromatography purified 6xHis-tagged STIP1 (5 µg). (lane 3) STIP1 following
incubation with TEV for 6xHis-tag cleavage and removal (5 µg) or (lane 4) (10 µg).
(lane 5) Molecular weight markers.
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2.3.2

Assignment of structural domains of STIP1
The individual folded functional domains of STIP1 (TPR1, DP1, TPR2A, TPR2B

and DP2) were isolated to facilitate study of STIP1 ligand interactions at the molecular
level. The molecular weights of individual STIP1 domains range from ~7-17 kDa (Figure
2.1A) making them amenable for study by NMR compared to full-length STIP1.
To the best of our knowledge, no amide backbone assignments are available for
the mammalian STIP1 domains, thus NMR experiments were conducted to assign the 1H15

N HSQC spectra of each of the domains. Backbone resonance assignments for 1HN, 15N,

13

Cα and 13Cβ were obtained for the TPR domains (TPR1, TPR2A and TPR2B) of

STIP1. For the TPR1 domain, 97% of the 1HN and 15N resonances of non-proline
residues, 94% 13Cα and 87% 13Cβ of all residues were assigned (Figure 2.2A and B). For
the TPR2A domain, 99% of 1HN and 15N resonances of non-proline residues, 95% 13Cα
and 96% 13Cβ of all residues were assigned (Figure 2.3A and B). Secondary structure
propensity scores calculated using the assigned 13Cα and 13Cβ chemical shifts predict
TPR1 and TPR2A to be composed of seven α-helical regions each separated by an
interconnecting disordered region with low α-helical propensity (Figure 2.2C and 2.3C)
[35]. No β-strand character is seen for the assigned residues. The predicted α-helical
propensity and their arrangement correlates with the x-ray crystal structures solved for
the human TPR1 and TPR2A domains and their cognate C-terminal Hsp ligands,
legitimizing the accuracy of the assignment [11].
For the TPR2B domain, 94% of the 1HN and 15N resonances of non-proline
residues, 93% 13Cα and 95% 13Cβ were assigned (Figure 2.4A and B). Currently, no
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high-resolution structural information is available for mammalian TPR2B. However; SSP
score predicts 7-α helical structure, which agrees with the TPR1 and TPR2A domains of
STIP1 and structurally aligns with the available yeast TPR2B structures (PDB: 3UPV)
solved by NMR (Figure 2.4C) [14].
The molecular functions of the DP domains of STIP1 remain enigmatic and no
ligand interactions have been identified to date. However; DP1 and the interconnecting
linker with TPR2A influences client activation in vivo and the DP2 domain has been
described as essential in yeast client activation. The solution NMR structure for the yeast
DP1 and DP2 domains were recently solved and revealed a novel α-helical fold, with the
α-helices of DP2 arranged to form a groove, which may serve as a binding pocket for as
of yet unidentified ligands [14]. Thus, we conducted NMR experiments to assign the DP
domains of mammalian STIP1. For DP2, 98% of 1HN and 15N resonances of non-proline
residues were assigned, 98% 13Cα and 98% 13Cβ (Figure 2.5A and B). SSP score
prediction indicated an all α-helical fold with an disordered C-terminal in agreement with
the solved yeast solution structure (Figure 2.5C) [14]. Five regions of α-helical
propensity were identified, which align with the solved yeast structure (PDB: 2LLW),
suggesting the fold is conserved between yeast and mammalian STIP1 [14].
Unfortunately, due to a large amount of signal degeneracy and poor signal
strength of the 13Cα and 13Cβ from the HNCACB and CBCA(CO)NH experiments, only
39% of the DP1 domain could be assigned with low confidence (Figure 2.6A). Further
experimentation is required to assign the remainder of the DP1 1H-15N HSQC.
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Figure 2.2. (A) 1H-15N HSQC spectrum and backbone assignment of 15N/13C labeled TPR1 domain of STIP1.
(B) Amino acid sequence of TPR1 domain with unassigned residues colored red. The N-terminal glycine is a non-native residue from
the TEV protease recognition site. (C) Secondary structure propensity (SSP) scores calculated for TPR1 based on 13Cα/β chemical
shifts [35].
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Figure 2.3. (A) 1H-15N HSQC spectrum and backbone assignment of 15N/13C labeled TPR2A domain of STIP1.
(B) Amino acid sequence of TPR2A domain with unassigned residues colored red. The N-terminal glycine is a non-native residue
from the TEV protease recognition site. (C) Secondary structure propensity (SSP) scores calculated for TPR2A based on 13Cα/β
chemical shifts [35].
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Figure 2.4. (A) 1H-15N HSQC spectrum and backbone assignment of 15N/13C labeled TPR2B domain of STIP1.
(B) Amino acid sequence of TPR2B domain with unassigned residues colored red. The N-terminal glycine is a non-native residue
from the TEV protease recognition site. (C) Secondary structure propensity (SSP) scores calculated for TPR2B based on 13Cα/β
chemical shifts [35].
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Figure 2.5. (A) 1H-15N HSQC spectrum and backbone assignment of 15N/13C labeled DP2 domain of STIP1.
(B) Amino acid sequence of DP2 domain with unassigned residues colored red. The N-terminal glycine is a non-native residue from
the TEV protease recognition site. (C) Secondary structure propensity (SSP) scores calculated for DP2 based on 13Cα/β chemical
shifts [35].
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Figure 2.6. (A) 1H-15N HSQC spectrum and backbone assignment of 15N/13C labeled
DP1 domain of STIP1.
(B) Amino acid sequence of DP1 domain with unassigned residues colored red. The Nterminal glycine is a non-native residue from the TEV protease recognition site.
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2.3.3

Monomeric state of STIP1 and TPR2A
Monomeric and dimeric models of STIP1 have been proposed for the biological

unit in solution [15, 36-38]. The TPR2A domain of STIP1 has been suggested as the
minimal fragment of STIP1 required for dimerization [36, 38-40]. The isolated TPR2A
domain has been reported to migrate as a dimer. Thus, we sought to determine the
structural unit of STIP1 and TPR2A to distinguish between monomeric and dimeric
models of TPR2A. Gel filtration of the TPR2A domain migrated as a monomer in
solution when compared to retention volumes of globular proteins of known molecular
weight (Figure 2.7A).
Analytical ultracentrifugation experiments were conducted to confirm the
monomeric state of STIP1 andTPR2A in solution. STIP1 presented a Mobs value of 55.3 ±
0.9 kDa, reasonably close to the predicted molecular weight of 62.6 kDa and consistent
with current monomeric models (see chapter 4). The TPR2A domain sedimented with a
Mobs of 17.2 ± 0.2 kDa, which is in close agreement to the inferred molecular weight of
monomeric TPR2A of 16.2 kDa based on the amino acid sequence (Figure 2.7B). These
results indicate TPR2A is indeed a monomer under these conditions.
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Figure 2.7. TPR2A behaves as a monomer in solution.
(A) Size-exclusion chromatography elution profile of TPR2A monitored by protein absorbance at 280 nm. TPR2A eluted as a single
species consistent to a monomer when compared to elution volumes of globular proteins of known molecular weight. (B)
Sedimentation equilibrium of AUC TPR2A obtained at rotor speeds 16 000, 20 000, 24 000 and 28 000 rpm (black, blue, red and
orange, respectively).
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2.3.4

Stability of TPR1 and TPR2A
Physiological ligands of STIP1 stability have been reported to vary under

different pH conditions. The majority of studies of the cellular prion protein (PrP) are
conducted under low pH conditions, thus we aimed to assess the stability of the TPR1
and TPR2A domains under various conditions to optimize future binding studies (See
Chapter 3).
The stability of TPR1 and TPR2A domains was investigated by circular
dichroism at various pH. Deconvolution of the TPR1 and TPR2A predicted 72.6 and
73.8% α-helical structure at neutral pH, respectively, which is in close agreement with
the x-ray crystallographic structures previously solved (Figure 2.8 and 2.9A). A decrease
in α-helical character and increase in the predicted disordered regions of the protein was
observed at low pH (~5). As well, thermal denaturation of both TPR1 and TPR2A
indicated a decrease in stability at low pH compared to neutral conditions indicated by a
decrease in the melting temperatures of approximately 10°C for both domains (Figure 2.8
and 2.9B). These results indicate binding studies at neutral pH conditions would be
optimal with TPR1 and TPR2A, which is at odds with most PrP studies being conducted
at pH 5 [41, 42]. However, low salt conditions at neutral pH have been reported for PrP
and will be used to assess TPR1 and TPR2A binding to PrP [43].
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Figure 2.8. TPR1 domain is predominately α-helical and demonstrates increased stability at neutral pH.
(A) CD spectra of TPR1 collected at pH 5 (red), pH 6 (blue) and pH 7 (black). (B) Thermal melts of TPR1 monitored by CD at 220
nm collected at pH 5 (red), pH 6 (blue) and pH 7 (black).
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Figure 2.9. TPR2A domain is predominately α-helical and demonstrates increased stability at neutral pH.
(A) CD spectra of TPR2A collected at pH 5 (red), pH 6 (blue) and pH 7 (black). (B) Thermal melts of TPR2A monitored by CD at
220 nm collected at pH 5 (red), pH 6 (blue) and pH 7 (black).
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2.3.5

Hsp90 binding to TPR2A
1

H-15N HSQC of the TPR2A domain collected in the absence and presence of

equimolar concentrations of Hsp90 C-terminal peptide produced large chemical shift
changes indicative of binding (Figure 2.10A). The magnitude of chemical shift
perturbations for traceable residues was calculated from the combined chemical shift
changes in 1H and 15N dimensions (Δω = |0.2 * Δ15N| + |Δ1HN|) in ppm. Residues
demonstrating the largest combined chemical shift changes (> 0.1 ppm) clustered to the
binding interface of the TPR2A-Hsp90 C-terminal peptide complex (Figure 2.10B).
Residues mapping to the carboxylate clamp (K229, N233, N264, K301 and R305) which
are involved in electrostatic interactions with the ‘EEVD’ motif based on the solved
crystal structure, demonstrated large chemical shift change further confirming the
assignment [11].
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Figure 2.10. Chemical shift mapping of Hsp90 C-terminal peptide binding to
TPR2A agrees with the solved crystal structure for the complex.
(A) Overlay of 1H-15N HSQC spectra of TPR2A in the absence (black) and presence
(red) of equimolar concentrations of Hsp90 C-terminal peptide. (B) Crystal structure of
TPR2A in complex with Hsp90 peptide (PDB: 1ELR) with traceable chemical shift
changes upon addition of Hsp90 peptide colored based on the magnitude of the combined
chemical shift changes in 1H and 15N dimensions [11].
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2.4

Discussion

STIP1 is composed of three TPR (TPR1, TPR2A and TPR2B) and two aspartateproline rich (DP1 and DP2) domains that function in a coordinated manner during Hsp70
and Hsp90 client protein refolding [12]. Initial peptide recognition by Hsp70 is facilitated
by the TPR1 domain, which is then transferred to TPR2B in the presence of Hsp90 by a
flexible linker adjacent to the DP1 domain [15], presumably to mediate transfer of the
client-bound Hsp70 to the HSP90 binding site in TPR2A. The minimal functional unit for
glucocorticoid receptor activation in vivo spans the C-terminal TPR2A-TPR2B-DP2
fragment [14, 44]. Hsp90 clients include a number of proto-oncogenic tyrosine kinases
and receptors including cyclin-dependent kinase-4, B-Raf, EGFR, HER2 and Bcr-Abl
[45-49]. Traditional approaches in Hsp90 targeting involve small molecular inhibitors
such as geldanamycin (GA) and the 17-AAG derivatives, which bind the ATP-binding
pocket of Hsp90. However; this class of therapeutics has demonstrated high levels of
toxicity in patients including anorexia, nausea, hepatoxicity [50].
An alternative approach has been explored in small molecule inhibitors that disrupt
Hsp90 interaction with TPR2A. These molecules share a 7-azaoeridine ring core and
inhibited Her2-positive human breast cancer cell lines [20]. The greater than 90%
assignments of the TPR domains of mammalian STIP1 can be used to screen and
optimize potential inhibitors of Hsp70 and Hsp90 binding and serve as potential cancer
therapeutics. Previous structural NMR studies have focused on the yeast STIP1
homologue that shares only approximately 40% sequence identity. Thus, the mouse
STIP1 assignments may be of great benefit in this approach as it is nearly identical to
human STIP1.
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The DP1 and DP2 domain solution structures have recently been solved by NMR,
which revealed a novel α-helical fold [14]. The yeast and mouse STIP1’s share
approximately 40% sequence identity; however, SSP score analysis of the 13Cα and 13Cβ
chemical shift deviations revealed a predicted α-helical arrangement of five α-helices
separated by short interconnecting linkers and is in agreement with the yeast structure
[14, 35]. The DP2 assignment may be used in the study of protein-protein interactions
between DP2 and potential ligands. As well, disruption of the recently identified
interactions with TPR2B of STIP1 may be of great interest, as the minimal functional
fragment of STIP1 spans the TPR2A-TPR2B-DP2 domains and DP2 contacts with these
TPRs may serve as another possible strategy to inhibit STIP1 function in oncogeneic
client folding [15].
Previous studies have disputed the monomeric state of STIP1 proposing alternate
dimeric models as the biological unit [36-38]. Gel filtration chromatography and
sedimentation equilibrium experiments presented here confirmed the monomeric state of
STIP1 and TPR2A. Current models strongly suggest a monomeric model for STIP1 Hsp
coordination with individual TPR domains facilitating concurrent interactions of Hsp70
and Hsp90 [14, 15, 40]. Previous discrepancies may have arisen due to the elongated
structure of STIP1 domain arrangement, deviating from predicted globular proteins [14,
51].
To optimize conditions for STIP1 domains identified to bind PrPC (TPR1 and
TPR2A) (See chapter 4), their stability was assessed at various pH. Most PrPC studies are
conducted at low pH (~5); however, TPR stability appeared diminished at low pH based
on circular dichroism. Thus, future studies with PrPC may benefit from neutral conditions.
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Indeed, PrPC interactions and structural studies have been reported at neutral pH in low
salt conditions.
The assigned backbone assignments of the TPR (TPR1, TPR2A and TPR2B) and DP
(DP1 and DP2) assignments provide the foundation for future NMR studies involved in
STIP1 ligands such as inhibitors of the Hsp90 pathway and the cellular prion protein
(PrPC). Stability screening of the PrPC interacting domains (TPR1 and TPR2A) will
facilitate the optimization of such studies.
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3

Domains of STIP1 responsible for regulating the PrPCdependent amyloid-β oligomer toxicity

3.1 Introduction
Neurotoxic assemblies composed of soluble oligomers of the amyloid-beta
peptide (AβO), derived from the sequential proteolytic cleavage of the amyloid precursor
protein (APP), are thought to be critical for neurotoxicity in Alzheimer’s disease (AD) [1,
2]. AβOs interact with numerous neuronal receptors or channel proteins resulting in
impairment of synaptic plasticity, oxidative stress, disruption of Ca2+ homeostasis,
inhibition of long-term potentiation (LTP) and neuronal cell death [3-6].
The cellular prion protein (PrPC) is a high affinity AβO receptor that has garnered
interest in relation to AβO-induced synaptic dysfunction [6-8]. PrPC is a highly expressed
cell surface glycoprotein which functions as a membrane scaffold for numerous ligands
resulting in modulation of cellular signaling events [9]. PrPC-AβO complex formation is
coupled to activation of Fyn kinase through mGluR5 resulting in deregulation of NMDA
receptors and calcium signaling [10-12]. Residues 23-27 and 95-110 of the disordered Nterminal region of PrPC have been proposed to mediate AβO binding [6, 13, 14].
Moreover, impairment of binding to residues 95-110 seems to alleviate AβO
neurotoxicity [6, 7]. While PrPC is not essential for all AβO-induced deficits, inhibition
of hippocampal LTP, impaired synaptic plasticity, loss of dendritic spines and neuronal
cell death seem to be PrPC-dependent [6, 8, 15]. Disruption of AβO binding by antibodies
directed against PrPC mitigate AβO induced neurotoxicity, suggesting that modulation of
AβO-PrPC interactions may be of therapeutic value in AD [7, 16-18]. Notably, a ligand of
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PrPC, stress-inducible phosphoprotein 1 (STIP1), can inhibit AβO toxicity in neurons in a
PrPC-dependent manner [19]. Moreover, decreased levels of STIP1 in mammalian
neurons or knockdown of STIP1 in C. elegans increases the toxicity of amyloid peptides
[19, 20].
STIP1 is a cellular cochaperone that coordinates Hsp70 and Hsp90 interactions
during folding of various cell cycle regulators and signal transduction proteins [21].
Interestingly, Hsp70, Hsp90 and STIP1 all can be secreted to the extracellular space
through non-canonical pathways by extracellular vesicles, where they can increase
cellular resilience by acting as extracellular chaperones or by signaling via membrane
receptors [22-25]. In particular, STIP1 is secreted by astrocytes into the extracellular
space, where it functions as a signaling molecule through PrPC [22, 26]. Complex
formation with PrPC induces neuroprotective and neuroproliferative signaling via PKA
and ERK pathways, respectively [27, 28], which is initiated by Ca2+ influx through the α7
nicotinic acetylcholine receptor (α7nAChR) in hippocampal neurons [29].
STIP1

is a modular

protein

composed

of

three structurally

related

tetratricopeptide repeat domains (TPR1, TPR2A and TPR2B), as well as two aspartateproline-rich regions (DP1 and DP2). Hsp engagement is facilitated through sequential
interactions with the TPR domains. Binding of Hsp70 and Hsp90 to the TPR1/TPR2B
and TPR2A domains of the cochaperone STI1P, respectively, allows the transfer of
clients from Hsp70 to Hsp90 [21, 30-33]. However, recent work suggests that interaction
between STIP1 and Hsp90 is comprised of more extensive interactions with the Nterminal domain and middle domain of Hsp90 [34, 35]. Previous work indicated that
amino acids 113-128 within PrPC are critical for STIP1 interaction [19, 26, 36]. Giving
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that STIP1 could potentially interact with PrPC, Hsp90 and Hsp70 in the extracellular
space, and this may modulate AβO toxicity, it is of importance to understand these
protein interactions at the molecular level.
Here we provide structural insights into the roles of individual domains of STI1P in
interacting with PrP as well as in inhibiting the AβO-PrP binding. In addition, the
potential of complex formation between STIP1, PrP, and Hsp90 is explored. Our results
reveal multiple domain interactions between STIP1 and PrP are involved in complex
formation and that the Hsp-interacting domains, TPR1 and TPR2A, directly inhibit AβO
binding to PrP and neuronal toxicity. In addition, we show that Hsp90 is able to influence
the interaction of STIP1 with PrP, inhibiting the neuroprotective role of STIP1 against
AβO insult.

3.2
3.2.1

Materials and methods
Protein expression and purification

pDEST17 expression vectors (Invitrogen) encoding various mouse STIP1
domains (i.e. full-length STIP1, TPR1 (residues 1 -118), DP1 (residues 119-216), TPR2A
(residues 217-352), TPR2B (residues 353-480) and DP2 (residues 481-542)) with an
additional N-terminal tobacco etch virus (TEV) cleavable 6xHis tag were transformed
into Escherichia coli (E. coli) BL21 (DE3) pLysS strain. E. coli were grown in standard
M9 minimal media at 37 oC to an OD600 of 0.9, at which point over-expression was
induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Temperature was
reduced to 22 oC and cultures were grown overnight.
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Proteins were initially purified by Ni2+-affinity chromatography using Ni
Sepharose 6 Fast Flow beads (GE Healthcare). 6xHis tag was cleaved by incubation with
6xHis tagged TEV overnight at room temperature. Following cleavage, TEV and 6xHis
tag were removed by an additional Ni2+-affinity chromatography purification [37]. For
nuclear magnetic resonance (NMR) spectroscopy, cells were grown in standard M9
minimal medium supplemented with 1 g/L

15

N-labeled ammonium chloride. Proteins

were flash-frozen in liquid nitrogen and stored at -80 oC for no longer than a month. All
NMR studies were conducted with freshly prepared protein.
N-terminal 6xHis tagged recombinant mouse PrP (23-231), (90-231) and (23-95)
in pRSETA was graciously provided by Dr. Kurt Wüthrich (ETH Zurich, Zurich,
Switzerland). Plasmids were transformed into E. coli BL21 (DE3) and cultures were
grown in lysogeny broth (LB) to an OD600 of 0.9. Expression was induced by the addition
of 1 mM IPTG and cultures were grown overnight at 22 oC. Inclusion bodies were
solubilized in 8 M urea containing 25 mM Tris, 500 mM NaCl, pH 7.5 and the resultant
denatured protein was purified using Ni2+-affinity chromatography. Solubilized protein
was refolded by dialysis against 10 mM sodium acetate, pH 5. Purified protein was
exchanged into 10 mM HEPES, pH 7, and the N-terminal 6xHis tag was cleaved by
overnight incubation with thrombin (Haematologic Technologies Inc.). Thrombin was
then removed by incubation with Benzamidine Sepharose 4 Fast Flow (GE Healthcare).
pET28 vectors encoding Hsp90β containing an N-terminal 6xHis tag separated by
a thrombin cleavage site (kindly provided by Dr. Johannes Buchner, Center for integrated
protein science (CIPSM) at the Department Chemie, Technische Universität München,
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Germany) were purified as described in [35]. Plasmid was transformed in E. coli BL21
(DE3) and cultures were grown in LB to an OD600 of 0.9 and induced with 1 mM IPTG.
Temperature was dropped to 30 °C and cultures were grown overnight. Bacterial pellets
were resuspended in 40 mM potassium phosphate, 400 mM KCl, 5 mM ATP, 1 mM
MgCl2, 6 mM imidazole, pH 8, and lyzed by French press at 10,000 psi. The resultant
protein was purified using Ni2+ chromatography. Eluted fractions containing Hsp90β
were combined and cleaved overnight by incubation with thrombin at 4 °C. Hsp90β was
further purified by gel filtration chromatography with a Superdex S200 column
equilibrated in 40 mM HEPES, 150 mM KCl, 5 mM MgCl2, pH 7.5.
AβOs were prepared from Aβ1-42 (rPeptide) as described previously [19]. Briefly,
Aβ1-42 was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) and SpeedVac
centrifuged generating peptide films. Aβ1-42 films were first re-suspended in DMSO to a
concentration of 1 mM and diluted in PBS to a final working concentration of 100 µM or
150 µM for NMR experiments. Peptides were incubated for 24 hours at 4 °C and stored
at -80 °C or used immediately.

3.2.2

NMR spectroscopy
Experiments were performed on a Varian Inova 600 MHz NMR spectrometer

equipped with xyz-gradient triple resonance probe at 25 °C in 5 mM sodium phosphate,
pH 7. Data were processed with NMRPipe and analyzed using NMRView [38, 39].
Chemical shift changes were mapped onto PrP (90-231) structure based on a previously
completed amide assignment (BMRB 16071 deposited in the BioMagResBank
(http://www.bmrb.wisc.edu))[40]. Binding of preformed AβOs to PrP (90-231) and (23-
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95) was observed by 1H-15N HSQC spectra collected in the presence and absence of
equimolar concentration (~85 µM) of AβO.
Backbone amide resonance assignments for TPR1 and TPR2A were obtained
from the BioMagResBank under accession numbers 18691 and 18689, respectively [37].
1

H-15N HSQC spectra of 15N-labelled TPR1 (50 µM) and TPR2A (50 µM) were collected

in the absence and presence of PrP(23-231) (50 µM). The magnitude of chemical shift
perturbations for traceable residues was calculated from the combined chemical shift
changes in the 1H and

15

N dimensions (Δω (ppm) = |0.2 * Δ15N| + |Δ1HN|) and mapped

onto the crystal structures of TPR1 (PDB: 1ELW) and TPR2A (PDB:1ELR) [30].

3.2.3

Protein-protein binding assay
10 µg of full-length PrP or N-terminal PrP (23-95) were immobilized onto Falcon

96-well polystyrene plates by incubation overnight at 4 oC. Non-specific sites were
blocked by incubation at room temperature for 1 hour with PBS-T (0.05%) containing
1% BSA. Plates were extensively washed with PBS-T and incubated with increasing
concentrations of STIP1, different STIP1 domains, or Hsp90 for 1 hour. Following
washing, bound proteins were detected using polyclonal antibodies directed towards
STIP1 (1:10,000) in PBS-T. After subsequent washing, wells were probed with
horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (1:5000) (Bio-Rad) for 1 hour.
The signal was visualized using o-phenylenediamine (OPD) and absorbance was
measured at 495 nm by microplate reader.
For assessing PrP influence on Hsp90 binding to STIP1, polystyrene plates were
covered with 10 µg of STIP1 and blocked as described above. After thorough washing,
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plates were incubated with various concentrations of PrP for 1 hour at room temperature,
followed by incubation with 2 µM Hsp90 for 1 hour. After subsequent washing, wells
were probed with rabbit anti-Hsp90 (1:1000, Cell Signaling) in PBS-T and bound Hsp90
was detected as outlined above.
TPR1

was

labeled

with

Fluoroscein-5-Maleimide

(Invitrogen)

as

per

manufacturer’s instructions to investigate competition of binding between TPR domains
to PrP. PrP was adsorbed on to black polystyrene plates as described above. Plates were
incubated with 1 µM fluorescein labeled TPR1 in the presence of various concentrations
of TPR2A. Following washing, fluorescence was measured at excitation and emission
wavelengths of 485/535 nm, respectively.

3.2.4

Surface plasmon resonance (SPR)
All SPR experiments were performed using a Biacore X system equipped with a

CM 5 sensor chip (GE Healthcare). The chip was uniformly coated with PrP (23-231)
using a standard amine-coupling method to an SPR signal of ~7000 resonance units
(RU). Ligands were injected in 10 mM HEPES, 150 mM NaCl, pH 7, over an association
period of 7 minutes at a flow rate of 5 µL/min. Off-kinetics were measured for an
additional 2 minutes following the end of sample injections. The CM5 chip surface was
regenerated using a 10 mM hydrochloric acid pulse for 1 minute at a flow rate of 100
µL/min between ligand injections.

3.2.5

Primary neuronal culture
Primary cultures of hippocampal neurons were obtained from E17.5 brains of

wild-type (Prnp+/+) mice from a C57BL6 background and prepared as previously
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described [19]. Hippocampi were aseptically dissected in HBSS (Invitrogen) and cells
were dissociated in 0.25% trypsin at 37 oC for 20 minutes. Proteolysis was inactivated by
re-suspension and dissociation of cells in Minimum Essential Media (MEM) (Invitrogen)
supplemented with 10% Fetal Bovine Serum, penicillin (100 IU), streptomycin (100
µg/mL) and glucose (0.5%). Cultures were maintained on poly-lysine-coated coverslips
or plates in Neurobasal Media (Invitrogen) supplemented with 2% B-27 (Invitrogen),
penicillin (100 IU), streptomycin (100 µg/mL) and L-glutamine (500 µM). Half of the
culture media was replaced every 3-4 days for the duration of the culture.

3.2.6

Cell death and viability assay
Hippocampal cultures (105 cells/dish) were maintained for 11 days in vitro (DIV)

then incubated with 1 µM AβO alone or in the presence of STIP1 (1 µM), TPR1 (2 µM),
TPR2A (2 µM) or DP1 (2 µM) for 48 hours. Cell death was assayed using LIVE/DEAD
Viability/Cytotoxicity Kit for mammalian cells (Invitrogen) as described by the
manufacturer. NIH ImageJ Cell Counter plug-in was used to calculate percentage of dead
cells (number of dead cells / (number of dead cells + number of viable cells)). For Hsp90
and AβO co-incubation experiments, cell cultures were incubated in the presence or
absence of Hsp90 (2 µM) and AβO (1 µM) with various concentrations of STIP1 (0-600
nM) and incubated for 48 hours. Cell death was assayed as described above.

3.2.7

AβO binding to primary hippocampal neurons
13 DIV cultured neurons (6 x 104 cells/dish) were treated for 15 minutes with 200

nM AβO alone or in the presence of 500 nM STIP1 or 1 µM TPR1, TPR2A and DP1 at
37 oC. Following incubation, cells were washed with KRH buffer (125 mM NaCl, 5mM
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KCl, 1.8 mM CaCl2, 2.6 mM MgSO4, 10 mM glucose, 5 mM HEPES, pH 7.2). Cells
were fixed with 4% paraformaldehyde for 20 minutes, washed with PBS, permeabilized
with 0.5% Triton X-100 in PBS for 5 minutes and blocked with 5% BSA (SigmaAldrich) in PBS for 1 hour at room temperature. Coverslips were incubated with
antibodies against γ-tubulin (1:500; Abcam) and amyloid-β (6E10, 1:350; Covance)
overnight at 4 oC. γ-tubulin and amyloid-β were detected by subsequent incubation with
secondary Alexa Fluor-488 and Alexa Fluor-633-conjugated antibodies (Invitrogen),
respectively, for 1 hour at room temperature. Immunofluorescence was detected on an
LSM510 confocal microscope equipped with a 63x/1.4NA oil-immersion objective lens.
The resultant fluorescence from neurites was integrated using NIH ImageJ software.

3.3
3.3.1

Results
Mapping of AβO interface on PrP

Previous studies have revealed that residues 95-110 of PrPC play a pivotal role in
mediating the interaction with AβO [6, 13, 16]. To refine the AβO binding-site on PrP in
a residue specific basis, we performed 1H-15N-HSQC experiments on

15

N-labelled PrP

(90-231) in the absence and presence of preformed AβO at a 1:1 molar ratio (Figure
3.1A). A significant decrease in signal intensity was observed for amide resonances
spanning residues 90-110 of the disordered N-terminal of PrP (Figure 3.1C), while no
new NMR peaks were observed in the PrP spectrum upon the addition of AβO. This loss
in signal intensity is likely due to peak broadening resultant from residues 90-110 binding
a large molecular weight species of AβO. No significant systematic changes in intensity
were observed for C-terminal resonances, suggesting the AβO binding site is highly
localized to the region spanning residues 90-110 of PrP (90-231) (Figures 3.1B and
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3.1C). The greatest decreases in peak intensity were observed in a glycine-rich region Nterminal of the sequence (residues 91-100). Interestingly, small but notable chemical
shifts were observed for C-terminal residues Leu125, His140, Gly142, Asn174 Val180,
Asn181, His187, Thr188 and Val189. These changes are likely due to weak transient
interactions with AβO or moderate conformational changes in PrP upon AβO binding.
Unfortunately, we were unable to assign the N-terminal of PrP, residues 23-95, due to the
high sequence redundancy and signal overlap of the spectrum. However, no significant
intensity changes or chemical shift perturbations were seen in the visible peaks of the
disordered N-terminal fragment PrP (23-95) in the presence of AβO (Figure 3.1D), which
stresses the importance of residues 90-110 in PrP-AβO complex formation.
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Figure 3.1. NMR reveals AβO associate with PrP residues 90-110.
(A) 1H-15N HSQC spectra of PrP (90-231) in the absence (black) and presence (red) of mature Aβ1-42 oligomers at a 1:1 ratio.
Residues that demonstrate a change in intensity (black arrows) or chemical shift changes (blue arrows) are noted. (B) Sample of onedimensional traces of peak intensity presented in (A). Residues 90-231 show a loss in signal intensity (Q91) while C-terminal residues
remain unchanged (E221). (C) Normalized peak intensity of PrP (90-231) plotted against residue number. (black line) Normalized
peak intensity level expected if no interaction took place between PrP (90-231) and Aβ1-42 oligomers. (red line) Average normalized
intensity decrease for all residues of PrP (90-231). (D) Normalized peak intensity of N-terminal PrP (23-95) peaks resolved in the1H15
N HSQC spectra in the presence of AβO. Due to signal overlap and sequence redundancy, the identity of the residues represented
by each peak could not be determined and the thus were assigned an arbitrary number. (black line) Normalized peak intensity level
expected if no interaction took place between PrP (23-95) and Aβ1-42 oligomers. (red line) Average normalized intensity decrease for
all peaks of PrP (23-95).
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3.3.2

Identification of STIP1 binding domains of PrP
We next sought to identify domains of STIP1 that bind PrP and the respective

regions of PrP that mediate the interactions. Previous studies have identified the TPR2A
domain of STIP1 as the major interaction site for PrP [19, 26, 36]. However, additional
regions of STIP1 may be involved in PrP binding due to the modular structure of STIP1
and the structural similarity shared between its TPR domains. Of particular interest were
STIP1 domains that specifically bind to PrP (90-231), since they may impair PrP-AβO
complex and provide a mechanistic basis for STIP1 neuroprotective properties against
AβO insult [19]. We tested binding of STIP1 and its domains using a multi-well proteinbinding assay. The domain boundaries of STIP1 are shown in Figure 2A. We confirmed
that STIP1 specifically bound PrP with high affinity (Figure 3.2B), Kd = 186±15 nM),
which is in agreement with previous studies [26]. Probing full-length PrP with individual
domains of STIP1 revealed that TPR1 (Kd = 1.2±0.2 µM) and DP1 (Kd = 600±50 nM), in
addition to the previously reported TPR2A (Kd = 800±130 nM) domain, can also interact
with PrP with comparable affinity, albeit lower than the affinity of full length STIP1
(Figure 3.2C). The DP1 domain of STIP1 was capable of interacting in a specific and
saturable manner with an N-terminal fragment of PrP (23-95), whereas the other domains
(TPR1 and TPR2A) did not (Figure 3.2D). The results strongly suggest that DP1 interacts
with the disordered N-terminal fragment of PrP (23-95), while PrP (90-231) binds TPR1
and TPR2A. The result is consistent with finding of previous studies showing that
residues 113-128 of mouse PrP is responsible for mediating the interaction with the
TPR2A domain of STI1P [26].
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Since TPR1 and TPR2A both bind the C-terminal fragment of PrP (90-231), we
investigated whether these domains can bind simultaneously or compete for binding to
PrP. TPR2A was capable of displacing fluorescently labeled TPR1 from its complex with
PrP in a concentration-dependent manner suggesting that binding of TPR1 and TPR2A to
PrP is mutually exclusive (i.e. the TPR1 and TPR2A binding sites on PrP are either
overlapping or in close proximity) (Figure 3.2E).
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Figure 3.2. DP1, TPR1 and TPR2A associate with PrP.
(A) Domain structure of STIP1 illustrating domain boundaries of three TPR (TPR1, TPR2A and TPR2B) and two DP (DP1 and DP2)
domains. (B) Polystyrene plates were pre-coated with 10 µg of PrP (23-231). Wells were probed with various concentrations of STIP1
(B) or STIP1 domains (C). STIP1 or domain immunoreactivity was detected using polyclonal anti-STIP1 antibodies and binding is
presented as OD495 values. (D) N-terminal PrP (23-95) was incubated with increasing concentrations of STIP1 domains. Binding of
the domains was detected as in (B and C) (n=3). (E) Immobilized PrP (23-231) was incubated with 1 µM fluorescein-labeled TPR1 in
the presence of various concentrations of TPR2A (n=4). Fluorescence of bound TPR1 was measured at excitation and emission
wavelengths of 485/535 nm, respectively.
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3.3.3

TPR1 and TPR2A prevent AβO binding to PrP
We have previously demonstrated that the TPR2A domain of STIP1 is able to

inhibit AβO binding to PrP, albeit with lower potency than full length STIP1 [19]. Given
that TPR1 and TPR2A can both bind to the C-terminal part of PrP (residues 90-231), we
investigated whether TPR1 can modulate AβO-PrP binding by surface plasmon
resonance (SPR). AβO injections showed a dose-‐dependent increase in response
monitored by SPR indicating binding (Figure 3.3A). Co-‐injection of STIP1 (62.5 nM)
with a constant concentration of AβO showed an appreciable decrease in the response
signal, suggesting inhibition of AβO binding to PrP. When co-injected with 125 nM
STIP1, the response from AβO was equal to that of an injection of 125 nM STIP1 alone,
suggesting complete inhibition of AβO binding (Figure 3.3B). Injections of TPR1 or
TPR2A domains also inhibited AβO binding to PrP in a dose-dependent manner, albeit at
higher concentrations than full-length STIP1 (Figures 3.3C and 3.3D, respectively). DP1,
which binds the N-terminal region of PrP (residues 23-95), did not have any effect on
AβO signals, consistent with this region being dispensable for AβO binding to PrP
(Figure 3.3E). Injection of each domain individually produced no detectable signal likely
due to their small size and sensitivity of the instrument (data not shown). These results
suggest that both the TPR1 and the TPR2A domains of STIP1 contribute to the direct
inhibition of AβO binding to PrP through interactions with PrP (90-231).
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Figure 3.3. TPR1 and TPR2A, but not DP1, inhibit AβO binding to PrP(23-231) in vitro.
PrP (23-231) was covalently immobilized on to a CM5 sensor chip. (A) Sensograms were collected for various AβO concentrations
binding to PrP (23-231). (B-E) Binding of AβO (2 µM) in the presence of increasing concentrations of STIP1 (B), TPR1 (C), TPR2A
(D) or DP1 (E).
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3.3.4

TPR1 and TPR2A inhibit AβO binding and toxicity in neurons
STIP1 is a neuroprotective regulator of AβO toxicity in hippocampal neurons	
   and

TPR2A domain by itself can reproduce this effect [19]. We therefore investigated
whether in vitro inhibition of AβO binding to PrP by TPR1 can also translate to a
beneficiary response in cultured primary mouse hippocampal neurons. Ectopic treatment
of neurons with recombinant STIP1, TPR1 or TPR2A domains in the presence of AβO
significantly decreased AβO binding to neuronal cell bodies compared to treatment with
AβO alone (Figures 3.4A and 3.4B). Co-treatment of neuronal cultures with AβO and
DP1 resulted in no visible effect on the amount of AβO bound to neurites. These
observations reflected our in vitro SPR results where only the TPR1 and TPR2A
domains, but not DP1, were able to inhibit AβO binding to PrP in a concentrationdependent manner. To assess if the decrease in AβO binding translated to inhibition of
AβO cytotoxicity, primary hippocampal neurons were treated with AβO in the presence
or absence of STIP1, TPR1, TPR2A or DP1 and incubated for 48 hours before assessing
the number of dead cells. AβO treatment alone increased cell death by ~15% compared to
basal levels. Co-treatment with STIP1, TPR1 or TPR2A rescued neuronal death from
AβO induced toxicity (Figure 3.4C). No discernible effect on cell viability was seen in
cells co-treated with DP1 and AβO compared to AβO treatment alone.
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Figure 3.4. STIP1, TPR1 and TPR2A inhibit AβO binding and toxicity in primary mouse hippocampal neurons.
(A) Representative images of 13 DIV neurons stained for γ-tubulin (red) and β-amyloid (green) after treatment with AβO in the
presence of STIP1, TPR1, TPR2A or DP1. (B) Quantification of A. (C) Comparison of neuronal cell death after 48 hours treatment
with AβO (1 µM) alone or in the presence of STIP1 (1 µM), TPR1 (2 µM), TPR2A (2 µM) or DP1 (2 µM). Experiments were
analyzed by one-way ANOVA, followed by Tukey’s post hoc test. ***P < 0.001, (n=3).
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3.3.5

Mapping of TPR1 and TPR2A interfaces mediating PrP
binding
To gain molecular understanding of the STIP1-PrP interactions, NMR

spectroscopy was used to map the binding interfaces of PrP on TPR1 and TPR2A on a
residue-specific manner. 1H-15N HSQC spectra of TPR1 and TPR2A showed comparable
amplitude of chemical shift perturbations upon addition of PrP (Figures 3.5A and 3.5C).
Resonances undergoing fast exchange (i.e. chemical shift difference between the free and
bound states is small compared to the rate of exchange between these two states) were
traced upon titration of PrP and were mapped onto the crystal structures of TPR1 and
TPR2A (Figures 3.5B and 3.5D). Notable chemical shift changes were observed for
residues Asp70, Trp71, Gly98, Lys100, His101 and Ala103 of TPR1, which form a
contiguous patch on the surface of the C-terminal part of the TPR1 structure (Figure
3.5B). In contrast, the TPR2A binding interface for PrP is more extensive, extending
diagonally across a hydrophobic cradle-shaped groove on one side of the TPR2A
molecule. Interestingly, this cradle-shaped groove is reserved for binding of the Cterminal peptide of Hsp90 to fulfill STIP1 cochaperone function during protein client
folding [30]. While critical contacts between TPR2A and Hsp90 C-terminal peptide made
by the carboxylate clamp (Lys229, Asn233, Asn264, Lys301, Arg305) of TPR2A did not
show the largest chemical shift changes upon binding of PrP, the partial overlap between
the Hsp90 and PrP binding interfaces suggests that Hsp90 and PrP may regulate each
other’s binding to STIP1 (Figure 3.6A). Therefore, we examined the potential for
cooperative binding and complex formation for STIP1, PrP and Hsp90.
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Figure 3.5. NMR indicates distinct regions of TPR1 and TPR2A interact with PrP(23-231).
(A) Graphical representations of chemical shift changes observed in 1H-15N spectra of 15N-labelled TPR1 or (C) TPR2A in the
presence of PrP(23-231). (B) Combined chemical shift changes mapped on to the crystal structure of TPR1 (PDB:1ELW) or (D)
TPR2A (PDB:1ELR). The protein structure images are generated using the Chimera molecular graphics software [54].
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STIP1 was adsorbed onto polystyrene plates and probed with PrP. Following
thorough washing of the complex; plates were incubated with a constant amount of
Hsp90 (4 µM) and bound Hsp90 was detected using antibodies directed against Hsp90.
Intriguingly, by increasing the concentration of PrP we achieved a saturable increase in
Hsp90 binding to the plate (Figure 3.6B). In contrast, no Hsp90 binding was detected to
PrP immobilized onto a polystyrene plate in the absence of STIP1 (Figure 3.6C). These
data suggest that PrP binding to STIP1 may induce conformational changes in the
complex, which in turn may increase the recruitment of Hsp90.
To investigate the potential relevance for the ternary complex formation of STIP1,
Hsp90 and PrP in AβO toxicity, primary mouse hippocampal neurons were incubated in
the presence of AβO (1 µM) and sub-optimal concentrations of STIP1. STIP1 caused a
dose-dependent decrease of AβO-induced cell death (Figure 3.6D). However, addition of
excess recombinant Hsp90 (2 µM) prevented STIP1 neuroprotection against AβO (Figure
3.6D). These results suggest that excess Hsp90 is able to block STIP1 neuroprotective
signaling, potentially by sequestering the protein or by interfering with signaling events
through PrP at the cellular membrane.
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Figure 3.6. Hsp90 inhibits STIP1 rescue of primary mouse hippocampal neurons
against AβO induced cell death.
(A) Chemical shift changes of PrP binding site on TPR2A (top) compared to the solved
crystal structure of Hsp90 C-terminal MEEVD peptide bound to TPR2A (bottom)
(PDB:1ELR). Residues of TPR2A involved in electrostatic interactions, hydrogen
bonding or Van der Waals interactions with Hsp90 peptide are labeled (black). The
protein structure images are generated using the Chimera molecular graphics software
[54]. (B) Polystyrene plates pre-coated with 10 µg of STI1P were first incubated with
increasing concentration of PrP, followed by incubation with Hsp90 (2 µM). Bound
Hsp90 was detected using polyclonal anti-Hsp90 antibodies. Binding is presented as
OD495 values (n=3). (C) Polystyrene plates were pre-coated with 10 µg of full-length PrP
(23-231). Wells were probed with various concentrations of Hsp90, followed by
detection of bound Hsp90 using polyclonal anti-Hsp90 antibodies. Binding is presented
as OD495 values (n=3). (D) Comparison of cell death of 13 d neurons after 48 hour
treatment with AβO (1 µM) and various concentrations of STIP1 (0-600 nM) in the
presence (red) or absence of HSP90 (2 µM) (black) (n=7). Experiments in the presence or
absence of Hsp90 were analyzed by two-way ANOVA, followed by Bonferroni’s post
hoc test. **P<0.01.
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3.4

Discussion

AβOs have been demonstrated to trigger synaptic dysfunction through interactions
with several neuronal receptors [3-5, 41]. Numerous studies have identified PrPC as a
high affinity receptor for AβOs and implicated the interaction in the transmission of
neurotoxic signaling [6, 15, 17]. Disruption of the PrPC-AβO complex has shown
therapeutic merit in the reduction of AβO toxicity [7, 19]. We have recently determined
that the cellular cochaperone and physiological PrPC ligand STIP1 is able to directly
inhibit AβO binding to PrPC and alleviate synaptic loss, depression of long-term
potentiation and neuronal cell death [19]. Therefore, understanding how this complex is
modulated is of importance.
The studies reported here provide molecular insights regarding the functional
modules of STIP1 that directly contribute to its recently described protective role against
AβO neurotoxicity and structural details of regions involved in binding to PrP. Our NMR
studies revealed significant resonance attenuations in the N-terminal unstructured region
of PrP encompassing residues 90-110 upon binding of mature preformed AβOs,
suggesting these residues mediate complex formation. These results are consistent with
previous observations, which indicated residues centered around 95-110 are essential and
sufficient for AβO binding to PrP [6, 7, 13, 14]. No significant chemical shift changes
were observed upon the addition of AβO to N-terminal PrP (23-95). A short highly basic
charge cluster ‘KKRPK’ located in the far N-terminal of PrP (residues 23-27) has been
suggested as a secondary AβO binding; however, other groups have reported near
identical AβO binding levels to PrP (90-231) as wild-type PrP [13, 42]. It is possible the
charge cluster acts as a secondary binding event following initial association of AβO to
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the primary binding site (residues 90-110). Thus, residues 23-95 may not participate in
binding in the absence of the high affinity site, which could explain the lack of large
chemical shift perturbations of PrP (23-95). Unfortunately, due to high sequence
redundancy and peak overlap problems owing to its disordered properties, we were
unable to assign residues 23-95 of PrP constructs. Thus, we cannot rule out the possibility
of minor, but localized chemical shift changes in residues 23-95 upon AβO titration.
Small chemical shift changes were noted for C-terminal PrP residues mapping to αhelices 1 and 2. These changes were much smaller in magnitude than those observed for
the primary AβO binding site. These findings are unexpected, since the globular part of
C-terminal portion of PrP is thought to be dispensable in its interaction with AβO. These
changes may result from conformational alterations in helix 1-helix 2 of PrP upon AβO
interaction. Alternatively, transient contacts between PrP molecules may be induced upon
binding to Aβ aggregates, stabilizing these complexes. Indeed, competition experiments
targeting an epitope spanning residues 131-153 effectively disrupted AβO binding to PrP
[7].
Our protein-protein binding assay results showed that full-length STIP1 binds to PrP
(23-231) with high affinity (Kd ~186 nM), which is in agreement with previous finding
[26, 36]. Surprisingly, binding of different domains of STIP1 to PrP (23-231) indicated
that not only previously identified TPR2A, but also the structurally related TPR1 domain
and the DP1 domain bind PrP with high affinity. TPR2A was capable of displacing TPR1
binding to PrP suggesting that they have overlapping binding sites or TPR2A is capable
of occluding the TPR1 binding site on PrP. Interestingly, DP1 domain bound to the N-
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terminal of PrP (residues 23-95), while the TPR domains did not, suggesting their
binding-site on PrP lies within residues 90-231. The recently solved NMR structures of
the DP1 and DP2 domains of yeast STIP1 reveal a novel α-helical fold composed of 6
and 5 helices, respectively [35]. Electrostatic potentials of DP1 illustrate a slightly
positive groove containing an additional α-helix absent in DP2, which stabilizes
secondary structure elements in DP1. Consequently, while both DP1 and DP2 share a
common tertiary structure, these distinct structural differences may indicate the inability
of DP2 to bind to the N-terminal of PrP.
Even though the function of the DP domains remains uncertain, the length of the
linker between TPR1 and TPR2A, which includes the DP1 domain, has recently been
proposed to facilitate transfer of Hsp90 from TPR1 to TPR2B during protein client
folding [33]. This is the first study to identify a direct ligand of DP1, suggesting the
domain may influence STIP1 binding to physiological ligands outside of its cochaperone
role in client protein refolding.
We confirmed by SPR the dose-dependent specific interaction between immobilized
PrP and AβO. Due to the abnormally long dissociation kinetics, consistent with other
studies, we were unable to quantitatively determine a binding constant for the interaction
[13, 19, 43]. Thus, the effects of STIP1 and individual domains on AβO were assessed
qualitatively based on the absolute magnitude of the response change. STIP1 effectively
inhibited AβO binding to PrP, abolishing the interaction at low nanomolar
concentrations, as demonstrated previously [19]. TPR2A and TPR1 domains were also
capable of inhibiting AβO binding to PrP albeit at much greater concentrations than
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STIP1, in agreement with our previous observations of STIP1 having a greater binding
affinity than the individual domains alone, supporting the notion of multiple binding
sites. DP1, the N-terminal PrP-binding domain of STIP1, had no discernible effect on
AβO binding with full-length PrP, which agrees with C-terminal PrP being the primary
AβO binding site. While DP1 may not actively disrupt AβO interaction with PrP, it may
contribute to the greater binding affinity of full length STIP1 binding to PrP and thus its
efficacy as an AβO inhibitor. Further investigation will be needed to determine the
molecular basis by which DP1, TPR1, and TPR2A domains inhibit PrP-AβO binding in
the full-length context.
AβO binding to neurons leads to cell death and impaired synaptic plasticity through
multiple signaling pathways [10, 44, 45]. Activation of aberrant NMDAR signaling by
AβO interaction to PrPC resulting in hyper excitability and activation of Fyn kinase has
been implicated in dendritic spine loss and neuronal cell death. We found that treatment
of primary mouse hippocampal neurons with STIP1, TPR1 or TPR2A reduced the
amount of AβO bound to the neuronal surface. Importantly, decrease in AβO binding
translated to rescue of neuronal cell death. Consistent with the inability of DP1 to inhibit
AβO binding in vitro, DP1 had no notable effect on binding of AβO to neurons or on cell
death. These results suggest that the TPR1 and TPR2A domains of STIP1 may cooperate
for the neuroprotective effects of STIP1 against AβO insult through PrPC.
Tetratricopeptide repeat motifs are highly degenerate 34 amino acids sequences
arranged into helix-loop helix structures forming adjacent anti-parallel helices [46]. The
high structural similarity between the TPR1 and TPR2A domains and their similar
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properties in inhibition of AβO binding to PrP led us to investigate whether these two
regions bind similarly to PrP at the structural level using NMR. Intriguingly, the binding
interfaces of TPR1 and TPR2A with PrP differ significantly. PrP bound TPR1 in a short
region encompassing the C-terminus of helix 6 and its respective interconnecting loop
region with helix 7. This region is far removed from the traditional TPR binding site
involved in protein-protein interactions.
The TPR2A interface extends diagonally across a hydrophobic cradle-shaped groove
on a single face of the TPR2A molecule [30]. Notably, this region overlaps with the
Hsp90 binding site of TPR2A, which is formed by electrostatic interactions with highly
conserved carboxylate clamp residues of TPR2A and the C-terminal EEVD motif of
Hsp90 [30]. Significant chemical shift changes were observed in residues corresponding
to the carboxylate clamp, as well as in additional residues occupying the cradle-shaped
groove that binds Hsp90.
While Hsp90 plays an important role in assisting and maintaining the proper folding
of many non-natively structured proteins, it has been implicated as detrimental in the
clearance of hyper-phosphorylated tau and Aβ, the pathological species in AD [47-49].
Along with this, Hsp90 inhibitors have been shown to be effective in facilitating tau
clearance and inhibiting Aβ neurotoxicity in mice [50]. In addition, actively secreted
Hsp90 also contributes to the regulation of extracellular client proteins [24, 51]. Given
that both STIP1 and Hsp90 are secreted, it is plausible that extracellular Hsp90 may
influence STIP1 interaction with PrP in the extracellular matrix or on the cell membrane.
Interestingly, while the TPR2A interfaces for Hsp90 and PrP binding show large
overlapping regions, PrP binding to STIP1 appears to promote ternary complex formation
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with Hsp90. PrP binding to STIP1 has been suggested to induce conformational changes
in PrP resulting in loss of helical structure [36]. The STIP1 induced unfolding may reveal
previously buried hydrophobic pockets on PrP, thus mimicking a misfolded protein and
resulting in the recruitment of Hsp90. Alternatively, Hsp90 binding to TPR2A domain of
STIP1 may induce structural rearrangements in both proteins, which may hinder STIP1
signaling through PrP. However; the relationship and potential interplay between STIP1,
Hsp90 and the PrP is poorly understood and will require further study regarding their
roles in the extracellular environment and implications in AD.
STIP1 has traditionally been considered as a cochaperone in the regulation of Hsp70
and Hsp90 client protein folding, however; strong evidence has revealed its importance
as a signaling molecule through PrP in neuroprotection [27, 29-31, 35, 52, 53]. The
modular structure of STIP1 allows for multiple domains to contribute to complex
formation with PrP, which have a direct influence on its protective role against AβO
insult. In addition, our studies indicate the possibility of ternary complex formation
composed of PrP, STIP1 and Hsp90, which may influence STIP1 neuroprotective
signaling against AβO toxicity in AD.
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4

Structural details of STIP1 complex with S100A1

4.1 Introduction
The S100-family of proteins comprises approximately 25 members involved in
several crucial biological processes including calcium (Ca2+) homeostasis, proliferation,
differentiation, inflammation and apoptosis [1-3]. These proteins are tissue and cellspecific homo/hetero dimers composed of two EF-hand helix motifs capable of Ca2+ ion
coordination [4]. Typically upon Ca2+-binding, α-helices III of each subunit undergo a
significant conformational change exposing a hydrophobic cleft, which represents the
binding site to various ligands [5]. Thus, S100-family is considered as Ca2+- dependent
regulators of several cellular pathways through multiple documented protein-protein
interactions [4]. Altered expression patterns of unique S100 proteins have been noted in
several disease states including different forms of cancer, cardiomyopathy and
neurodegenerative diseases such as Alzheimer’s disease (AD) and serve as clinical
diagnostic biomarkers [6-9].
Calcium serves as a ubiquitous signaling molecule in neuronal activation whose
deregulation is a common hallmark in AD causing synaptic dysfunction[10]. Ca2+ binding proteins play an important role in regulating Ca2+ homeostasis and modulating
protein-protein interactions. Consistent in this capacity, a number of S100-family
members have been implicated in aberrant AD signaling [6, 11, 12]. S100A1 is
abundantly expressed in skeletal muscle, cardiomyocytes and neurons [6, 8, 13]. S100A1
has been found to regulate amyloid precursor protein (APP) processing, tau
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phosphorylation and Aβ oligomer induced neuronal cell death [14]. In addition, studies
have revealed roles for S100A1 in the heat-shock protein response, regulating Hsp70 and
Hsp90 binding to stress-inducible phosphoprotein 1 (STIP1) during client protein
refolding [15, 16].
STIP1 is a cellular co-chaperone, which coordinates client protein transfer from
Hsp70 to Hsp90 during protein folding of various cellular ligands including numerous
oncogenic kinases and transcription factors [17]. STIP1 is composed of three structurally
related tetratricopeptide repeat (TPR1, TPR2A and TPR2B) domains and two aspartate
and proline rich DP (DP1 and DP2) domains. TPR domains are 34-amino acid degenerate
consensus motifs arranged in tandem forming a series of anti-parallel amphipathic αhelices [18]. They are common protein-protein interaction modules involved in numerous
cellular processes including cell cycle regulation, transcription and protein folding [19].
TPR2A and TPR2B mediate interactions between the C-terminal EEVD motif of Hsp90
and through a series of contacts located in the middle domain of Hsp90 [17, 18, 20, 21].
Hsp70 coordination involves binding to the TPR1 and TPR2B domains of STIP1.
S100A1, S100A2 and S100A6 family members have been identified as STIP1
ligands, forming molecular complexes through interactions with the TPR domains of
STIP1 [15, 16]. S100A2 and S100A6 association has also been shown to inhibit Hsp70
and Hsp90 binding to STIP1 in vitro and in cell culture upon Ca2+ stimulation,
implicating their function in the STIP1-directed protein-folding relay. However, the
molecular details of S100 binding to STIP1 remain largely unknown.
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The present study employed NMR, analytical ultracentrifugation and isothermal
titration calorimetry (ITC) to define the molecular details of S100A1 binding to STIP1.
Our results reveal that each TPR domain is capable of simultaneous binding to a single
S100A1 dimer with varying affinities and thermodynamic parameters in the full-length
STIP1 molecule. Each TPR domain associates with S100A1 through a common binding
site, spanning α-helices III and IV of S100A1 in a Ca2+-dependent manner. While nuclear
magnetic resonance (NMR) studies for each TPR domain noted binding, a global loss in
peak intensity due to line broadening prevented chemical-shift mapping of the S100A1
binding site on each TPR domain of STIP1.

4.2
4.2.1

Materials and methods
Protein purification

Recombinant STIP1 or individual TPR domains (TPR1 (residues 1-118), TPR2A
(residues 217-352) and TPR2B (residues 353-480)) were cloned into pDEST17
expression vectors (Invitrogen-ThermoFisher Scientific). Each construct contained an
additional N-terminal 6xHis-tag joined by a cleavable tobacco etch virus (TEV)
recognition site to facilitate tag removal. Individual constructs were transformed into
Escherichia coli (E. coli) BL21 (DE3) pLysS strain and grown in standard M9 minimal
media at 37 °C to an OD600 of 0.9. Expression was induced with 1 mM isopropyl β-D-1thiogalactopyranoside (IPTG) and cultures were grown at 22 °C overnight. Protein
samples for NMR spectroscopy were expressed in standard M9 media supplemented with
1 g/L 15N-labeled ammonium chloride.
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Recombinant STIP1 proteins were purified by Ni2+-affinity chromatography using
Ni Sepharose 6 Fast Flow beads (GE Healthcare Life Sciences). 6xHis-tag cleavage was
achieved by incubation with 6xHis tagged TEV overnight at 22°C. TEV and 6xHis tag
were subsequently removed by additional Ni2+-affinity chromatography.
pETDuet vector encoding S100A1 (kindly provided by Dr. Gary Shaw) was
transformed into E. coli BL21(DE3)-RIL and cultures were grown in standard M9
minimal medium or in M9 supplemented with 1g/L 15N-labeled ammonium chloride for
NMR spectroscopy studies. Cultures were grown to an OD600 of 0.9 and induced with 1
mM IPTG and grown overnight at 22°C. The bacterial pellet was resuspended in 50 mM
Tris-HCl, 5mM MgCl2, pH 8.0 and lyzed by French press at 10,000 psi. Cellular debris
were pelleted by centrifugation at 40,000 x g for 30 minutes. Supernatant was filtered
through a 0.45 µm syringe filter (Thermo Scientific) and loaded onto a 2 mL HiTrap Q
anion exchange column (GE Healthcare) equilibrated in Buffer A (25mM Tris-HCl, 1
mM EDTA, 1 mM DTT, pH 8.0) using a AKTA FPLC (GE Healthcare) at a flow rate 1
mL/min. The column was washed with 10 column volumes of Buffer A and subsequently
eluted by a 20-column volume linear gradient of Buffer A with 1 M NaCl. Fractions
containing S100A1 were pooled and the CaCl2 concentration was adjusted to 5 mM.
Fractions were incubated with phenyl-Sepharose resin (Amersham Bioscience) for 1 hour
at room temperature and washed with 25 mM Tris-HCl, 100 mM NaCl, 1 mM DTT,
1mM CaCl2, pH 8.0. Bound S100A1 was eluted with 25 mM Tris-HCl, 100 mM NaCl, 1
mM DTT, 5 mM EGTA, pH 8.0 and all proteins were dialyzed into 10 mM HEPES,
100mM NaCl, 1 mM DTT, pH 8.0 with 5 mM CaCl2 or 5 mM EGTA for further studies.

114

4.2.2

Analytical ultracentrifugation – sedimentation equilibrium
Analytical ultracentrifugation (AUC) experiments were preformed at 20 °C on

STIP1 (18 µM) and S100A1 (30 µM), or STIP1 and S100A1 mixtures containing 8 µM
and 48 µM of each protein, respectively, using a Beckman Optima XL-A Analytical
Ultracentrifuge equipped with an An-60Ti rotor containing six-channel Epon-charcoal
centerpieces and 1.2 cm path length (Biomolecular Interactions and Conformations
Facility, University of Western Ontario). Absorbance measurements were collected at
250 nm in 0.002 cm radial steps and averaged over 10 scans. Sedimentation equilibrium
measurements were collected at rotor speeds of 12 000, 15 000 and 18 000 rpm (STIP1)
or 20 000, 24 000 and 28 000 rpm (S100A1) or 7 000 and 10 000 rpm (STIP1-STIP1
complex). Data was fit to the following global single-ideal species model equation using
GraphPad Prism

(Equation 1) where C is the concentration of protein at radius x, C0 is the concentration at
initial radius x0, ω is the angular velocity, vbar is the partial specific volume of the protein,

ρ is the solvent density, R is the ideal gas constant, T is the absolute temperature, I0 is the
baseline offset and Mobs is the fit of the molecular weight based on sedimentation data.
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4.2.3

Isothermal titration calorimetry (ITC)
Binding of STIP1 and TPR domains to S100A1 was measured using a

MicroCal VP-ITC calorimeter or Nano-ITC (TA Instruments) at 25°C. All protein
concentrations for S100A1 correspond to dimer concentrations. Twenty-five to 30
aliquots of 5 µL STIP1 (60 µM) or individual TPR domains (~150 µM) were titrated to
S100A1 (~ 30-70 µM). Buffer blank or ligand into buffer titrations demonstrated
negligible heats of binding and heats of dilution, respectively. Each titration was
replicated in duplicate. Isotherms were fit to a single-site binding model using Origin or
NanoAnalyze software provided by the manufacturer, where Kd is the dissociation
constant, n is the stoichiometry of binding and ΔH and ΔS represent the change in
enthalpy and entropy of binding, respectively.

4.2.4

Nuclear magnetic resonance (NMR) spectroscopy
Nuclear Magnetic Resonance (NMR) Spectroscopy experiments were preformed

on a Varian Inova 600 MHz NMR spectrometer equipped with xyz-gradient triple
resonance cryogenic probe at 25 °C. Backbone resonance assignments for TPR2B (~400
µM) were obtained from HNCACB and CBCA(CO)NH experiments prepared in 50 mM
sodium phosphate, 50 mM NaCl, 1 mM DTT, pH 7. Backbone amide resonance
assignments for TPR1, TPR2A and S100A1 were obtained from the BioMagResBank
under accession numbers 18691, 18689 and 18231, respectively. NMR spectra were
processed with NMRPipe and analyzed by NMRViewJ or CARA [22-24]. 1H-15N HSQC
spectra of 15N-labeled S100A1 (~ 200 µM) were collected in the presence of increasing
TPR domains (~ 0-200 µM). The reciprocal of the binding experiments were collected
with 15N-labeled TPR domains (TPR1, TPR2A and TPR2B) at identical concentrations.
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4.3
4.3.1

Results
Multiple S100A1 dimers bind to STIP1 with different affinities

Previous studies have demonstrated that S100-family of proteins complex with
STIP1 through its structurally related TPR domains; however, the biochemical details of
S100 binding to STIP1 to date are poorly understood [16, 25]. We have used isothermal
titration calorimetry (ITC) to measure the binding affinities and characterize the
thermodynamic details of the STIP1-S100A1 complex.
S100A1 bound to full-length STIP1 with high affinity in the presence of Ca2+. No
heat change was detected upon Ca2+ chelation, suggesting STIP1-S100A1 complex
formation is Ca2+ dependent (Figure 4.1A and 4.1B). The change in enthalpy (ΔH) upon
STIP1 titration to S100A1 is highly endothermic indicating complex formation is
entropically driven and likely involving a large number of hydrophobic contacts (Figure
1.A). Consistent with this hypothesis, Ca2+ binding to S100-family of proteins results in
structural rearrangement of the EF-hand α-helical motifs resulting in the exposure of a
hydrophobic interface involved in numerous S100-family ligand interactions [7]. The
stoichiometry of binding of STIP1 to S100A1 deviated dramatically from a single-site
binding model, suggesting multiple S100A1 dimers bind a single molecule of STIP1.
This agrees with previous studies demonstrating the S100 family members S100A2 and
S100A6 bind to multiple individual TPR domains (TPR1, TPR2A and TPR2B) of STIP1
[16]. Interestingly, only a single inflection point is seen in the binding isotherm and it
was not possible to distinguish the different binding equilibria.
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Figure 4.1. STIP1 binds multiple S100A1 dimers in a Ca2+-dependent manner.
Isothermal titration calorimetry thermogram of STIP1 binding to S100A1 in the presence
(A) of 5mM CaCl2 or (B) 5 mM EGTA.
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Due to the potential complexity of STIP1 binding to S100A1, measurements were
conducted on individual TPR (TPR1, TPR2A and TPR2B) domains of STIP1 to obtain
greater insight into complex formation. Binding affinities between the individual TPR
domains and S100A1 differed significantly, approximately 15-fold range between the
strongest and weakest interaction (Figure 4.2A. 4.2B, and 4.2C) (Table 1). Due to the
relatively weak binding of the TPR2A domain compared to the other TPR domains
(TPR1, TPR2B), the enthalpy and binding affinity could not be accurately determined for
this interaction (Kd = ~ 15 µM). TPR2B bound to S100A1 with the highest affinity (Kd =
0.76 ± 0.01 µM), approximately 6 folds greater than TPR1 (Kd = 4.37 ± 0.1 µM). The
enthalpies of binding to each TPR domain were endothermic in agreement with the
values seen for full-length STIP1 and confirm S100A1 complex formation to each TPR
domain is entropically driven.
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Table 1. Thermodynamic parameters of TPR domains of STIP1 binding to S100A1.
TPR domain na

Kd (µM)b

ΔHb (kcal/mol)

TΔSb (kcal/mol) ΔGb (kcal/mol)

STIP1

0.19 0.59 ± 1.2

72.9 ± 5.8

81.4

-8.5 ± 6.0

TPR1

0.95 4.37 ± 0.1

55.4 ± 1.0

62.6

-7.2 ± 1.0

TPR2A

-

-

-

-

TPR2B

0.96 0.76 ± 0.1

20.8 ± 0.3

29.1

-8.3 ± 0.3

a

-

Binding stoichiometry of dimeric S100A1 and the TPR domains of STIP1
Kd is the dissociation constant and ΔH, ΔS and ΔG are the change in enthalpy, entropy
and Gibbs free energy upon binding at T=298.15 K, respectively.
b
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Figure 4.2. The TPR domains of STIP1 bind a single S100A1 dimer with various affinities.
Isothermal titration calorimetry thermogram of S100A1 binding to (A) TPR1, (B) TPR2A or (C) TPR2B domains of STIP1.
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4.3.2

STIP1 binds to three S100A1 dimers
Studies have indicated additional S100 proteins complex with STIP1 through

TPR-motif interactions in each domain through pulldown experiments [16]. These
include S100A2 and S100A6, but not S100B, S100A4, S100A10, S100A11, S100A12 or
S100A13 [13]. Thus, this is not a property shared by all S100 family members. The S100
proteins identified to bind STIP1 differed in the number of S100 dimers that bind a single
molecule of STIP1. Our ITC results did not fit perfectly to a single-site model, thus we
could not say for certain the stoichiometry of binding of S100A1 to STIP1. Thus, AUC
experiments were conducted to gain additional insights into the stoichiometry of binding
of S100A1 to full-length STIP1. S100A1 exhibited a Mobs value of 24.2 ± 0.2 kDa,
consistent with previous studies suggesting S100A1 exists as a homodimer in solution of
a calculated molecular weight of 21.1 kDa based on the amino acid sequence (Figure
4.3A). Alternatively, STIP1 presented a Mobs value of 55.3 ± 0.9 kDa, reasonably close to
the predicted molecular weight of 62.6 kDa and consistent with current monomeric
models of STIP1 function in solution during Hsp70 and Hsp90 client protein transfer
(Figure 4.4B). AUC of STIP1 at saturating concentrations of S100A1 revealed the
formation of a larger molecular weight species with a Mobs of 126.1 ± 1.2 kDa (Figure
4.4C). These results are in agreement with a single S100A1 dimer binding to each of the
three TPR domains of STIP1, which would have an inferred molecular weight of 125.9
kDa.
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Figure 4.3. A single STIP1 molecule binds three S100A1 dimers simultaneously.
Sedimentation equilibrium of AUC (A) S100A1 obtained at rotor speeds 20 000, 24 000 and 28 000 rpm (black, blue and red,
respectively), (B) STIP1 measured at 12 000, 15 000 and 18 000 rpm (black, red, blue, respectively) or(C) STIP1-S100A1 complex
collected at 7 000 and 10 000 rpm (black and red, respectively). Lines represent global fits to a single species model as described in
Equation 1.
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4.3.3

S100A1 shares a common interface when binding each TPR
domain
The disparity in affinities and significant differences in thermodynamic properties

of S100A1-TPR interactions suggests there are differences in the binding interfaces
between these interactions. Thus, we used nuclear magnetic resonance (NMR)
spectroscopy to define residues involved in complex formation at the molecular level.
Titration of 15N-isotopically labeled S100A1 with increasing concentrations of each TPR
domain (TPR1, TPR2A and TPR2B) resulted in a systematic global reduction in peak
intensity (Figure 4.4). The loss in signal is likely the result of line broadening through
enhanced relaxation, the consequence of increased molecular weight of the S100A1-TPR
complex (37.4 kDa) in relation to the unbound S100A1 spectrum (21.1 kDa).
Interestingly, a significantly greater loss in peak intensity was observed in residues
localized to a continuous region spanning α-helices III and IV of S100A1 (Figure 4.4A,
B and C). Residues of S100A1 showing the largest peak intensity attenuations upon
addition of each TPR domain were mapped to an identical region suggesting that they
share a common binding site on S100A1.
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Figure 4.4. TPR domains of STIP1 share a common binding interface on S100A1.
Graphical representations of chemical shift changes observed in 1H-15N spectra of 15N-lablled S100A1 in the presence of (A) TPR1,
(B) TPR2A or (C) TPR2B (left)(red line: average decrease in signal intensity upon TPR titration; black line: one standard deviation
from the mean decrease in signal intensity) Chemical shift changes mapped on to S100A1 structure (PDB:2LP3)[33] (right). Regions
of S100A1 that demonstrated a greater than one standard deviation from the mean average decrease in signal intensity are colored in
red.
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The similarity of the S100A1-TPR binding regions suggests differences in affinity
and thermodynamics are likely due to differences in amino acid composition on the
individual TPR domains. To determine the regions of each TPR domain involved in
S100A1 complex formation, the reciprocal experiment was conducted where 15N-labeled
TPR domains were titrated with S100A1. A global decrease in signal intensity was
observed for each TPR spectrum consistent with the results obtained in the S100A1
spectra (Figure 4.5A, B and C). Unfortunately, no significant localized deviation from the
global decrease in signal intensity was observed for each TPR titration. This result
prevented accurate mapping of the S100A1 binding site on each TPR domain. Further
study is required to identify the S100A1 binding site in each TPR domain of STIP1 by
complementary techniques.
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Figure 4.5. Graphical representations of chemical shift changes observed in 1H-15N spectra of 15N-labelled (A)TPR1, (B)
TPR2A or (C) TPR2B in the presence of S100A1.
(red line: average decrease in signal intensity upon TPR titration; black line: one standard deviation from the mean decrease in signal
intensity)
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4.4

Discussion

The studies presented here provide molecular details of the interactions between
S100A1 and STIP1. ITC thermograms indicated a high affinity interaction between
S100A1 and full-length STIP1. The stoichiometry of binding (n) differed dramatically
from a single one-site model; however, only a single inflection point was evident in the
thermograms, suggesting multiple binding sites with similar thermodynamic properties.
The possibility of multiple binding sites complicated fitting the isotherm to a single
binding model, thus we investigated binding to individual TPR domains. Previous studies
have demonstrated that each individual TPR domain of STIP1 is capable of binding
related S100 family members (S100A2 and S100A6) [16]. However, these studies were
limited to affinity pull down experiments and the thermodynamic details of S100 binding
to each TPR domain and S100 proteins were lacking. Though similar in structure,
S100A2 and S100A6 dimers have been shown to bind STIP1 at stoichiometric ratios of
4:1 and 2:1 by pull-down experiments, respectively [16]. Steric hindrance or
conformational rearrangements in STIP1’s modular structure may alter the binding
capacity of STIP1 for S100 proteins, even though individually each TPR domain
possesses the capacity to bind S100 proteins.
ITC binding experiments of each TPR domain titrated to S100A1 revealed
significantly different binding properties. Binding affinities differed approximately 20
fold between the tightest bindings TPR2B (Kd = 0.8 µM) and weakest, TPR2A (Kd
estimated to be ~ 15 µM). While representative of TPR affinities to S100A1, we cannot
rule out potential cooperatively in binding in the context of the full-length protein. TPR
domains are believed to function as ancient protein-protein interaction modules and are
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often seen in tandem across multiple TPR containing proteins [26]. It is therefore not
uncommon for a single ligand to interface with multiple TPR domains, as is seen with the
prototypical and best characterized STIP1 binding partners, Hsp70 and Hsp90 [21, 27,
28]. Interestingly, in the case of Hsp70 and Hsp90 coordination, while each TPR domain
is capable of recognizing C-terminal region ‘EEVD” motifs of Hsp70 and Hsp90, the
individual TPR domains take on different roles to regulate binding properties of the fulllength molecule [18]. TPR1 and TPR2B show preference for Hsp70 binding, while
Hsp90 interacts with TPR2A-TPR2B. In addition, it appears that Hsp70 and Hsp90 are
not capable of binding each TPR domain concurrently due to steric hindrance or
conformational changes in full-length STIP1. The binding model for S100A1 differs in
that each TPR domain is occupied by an S100A1 dimer.
Sedimentation equilibrium AUC experiments confirmed the dimeric and monomeric
native states of S100A1 and STIP1, respectively. There has been some disagreement as to
the native state of STIP1 in solution as studies have suggested monomeric and dimeric
forms [21, 29-31]. The most detailed and recent model of STIP1 suggests a large
elongated structure in the free state and attributing previous dimeric models as the result
of an atypical elongated structure and large hydrodynamic radius of the full-length
protein [29, 32].
To date numerous TPR interactions have been described between S100A1 and
additional S100 family members. Coincidentally, a large number of the TPR-motif
interactions identified thus far segregate into additional co-chaperones and members of
the heat shock protein complex, such as FKBP52, Cyp40, PP5, CHIP [15, 25]. These cochaperones utilize TPR motifs to associate with Hsp70 and Hsp90 influencing many
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cellular processes. Thus, these studies implicate S100A1 and additional S100 proteins in
a regulatory network of heat shock protein machinery in protein client refolding.
S100 interactions with chaperone and co-chaperone proteins vary on their dependence
on Ca2+ for protein binding, suggesting differing modes of interaction, though structural
details involving these interactions are scarce. Therefore, we used NMR chemical shift
perturbation mapping to determine the binding interfaces between S100A1 and the
individual TPR domains (TPR1, TPR2A and TPR2B) of STIP1. Titrations of 15N-labeled
S100A1 with each TPR domain lead to a systematic decrease in signal intensity.
Chemical shift mapping revealed a significant decrease in intensity for residues localized
to α-helices III and IV of EF-hand motifs. Each S100A1 subunit is composed of a 14residue N and 12-residue C-terminal calcium-binding loop [33]. The latter is situated
between helices III and IV. NMR solution structures of the apo- and Ca2+ bound forms
indicate Ca2+ binding triggers a large conformational change resulting in the reorientation
of α-helix III by approximately 100° and exposing a large hydrophobic region in α-helix
IV[5]. The Ca2+-dependant binding of STIP1 presented by ITC and the significant NMR
peak intensity changes in α-helix IV upon TPR binding agrees with the interaction
localizing to an interface spanning α-helix IV and provides rationale for the interaction
being Ca2+ dependant. The mapped hydrophobic interface on S100A1 for TPR binding is
consistent with a variety of S100-family member ligands that associate in a Ca2+dependant manner [4]. Interestingly, the stoichiometry of complex formation determined
by ITC and AUC suggest a single TPR domain binds a single S100A1 homodimer. This
differs from many S100-target peptide complexes solved to date which display
symmetric binding [34-36]. However; these studies involved short peptides
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corresponding to ligand binding regions, which may not be representative of full-length
proteins, where alternate structural elements may occlude binding to both S100
monomers.
While NMR spectra of each TPR domain did show a global peak intensity change
upon S100A1 titration, the binding interface could not be mapped to a particular region.
The local effects of binding may be masked due to intermediate exchange rates or the
large size of the complex. However, comments on particular regions of the TPR domains
that may potentially be involved in binding to S100A1 can be made using the structural
information available. Crystal structures of the TPR1 and TPR2A domains reveal a
hydrophobic cradle shaped groove extending on one side of each TPR domain [18]. This
site serves as the binding interface of the disordered C-terminal ‘EEVD’ motifs of Hsp70
and Hsp90, respectively, and is the canonical binding site for other TPR-motif ligands.
However, due to the concave nature of the mapped S100A1 binding interface and this
canonical TPR binding site, it is unlikely the binding site of S100A1. Steric clashing
generated by α-helices III of S100A1 subunits and the N and C terminal α-helices of
each TPR domain would likely prevent binding to α-helices IV of S100A1 unless
significant conformational deviations occur in the bound state of the complex. As well,
the similarity of the binding site on S100A1 for each TPR domain suggests that
differences in binding and thermodynamic properties in the interactions is likely due to
the amino acid compositions and residue contacts formed by each TPR domain on the
shared S100A1 binding site. Further, study of the TPR domain-binding site for S100A1 is
needed to identify regions involved in complex formation.
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The S100 families of binding proteins have been shown to demonstrate unique and
characteristic expression profiles in multiple human diseases including different forms of
cancer and neurodegenerative disorders such as ALS and AD [6, 7, 12]. Multiple
interactions have been documented between S100A1 and other S100-famliy members
with TPR containing proteins, with a large number S100A1 ligands identified to be
involved in the Hsp complex machinery, though the molecular details of these
interactions has not previously been described. Our studies describe the molecular details
of STIP1 interaction with S100A1 and its TPR domains, which may influence STIP1
function upon S100A1 deregulation in multiple disease states.
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5

Summary
Stress-inducible phosphoprotein 1 (STIP1) has been extensively studied as a

cochaperone of the Hsp70/Hsp90 protein client folding machinery [1-4]. STIP1 couples
transfer of immature or abnormally folded proteins from Hsp70 to Hsp90 during the
client folding cycle [5]. It is now accepted that extracellular STIP1 can function as a
potent neuroprotective and neuroproliferative signaling molecule through complex
formation with the cellular prion protein (PrPC) [6-10]. The resultant signaling cascade
rescues neurons from various cellular stressors including staurosporine-induced
programmed cell death and ischemia [6, 11]. This neuroprotection has recently been
extended to Aβ oligomer (AβO) toxicity, suggesting STIP1 signaling as an endogenous
protective mechanism in Alzheimer’s disease (AD) [12]. In addition, recent studies have
identified particular members of the S100- family of Ca2+ sensors as STIP1 ligands [13].
S100 proteins altered expression has been implicated in several diseases including
cardiomyopathy, cancer and AD [14].
Detailed structural studies have been conducted to dissect STIP1 co-chaperone
interactions with Hsp machinery [1-3, 15]. In contrast, few details are available
concerning STIP1 interaction with PrPC and the S100-famliy of proteins [13, 16]. The
work presented in this thesis addressed the molecular details of STIP1 interactions with
PrPC and S100A1 proteins in order to provide a better understanding of alternate STIP1
complexes beyond Hsp interactions and their role in AD.
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5.1 Structural characterization of STIP1 domains
The majority of NMR studies to date involving STIP1 have focused on the yeast
homologue [2, 3, 15]. Where as complementary x-ray crystallographic data and other
biophysical techniques suggest a conserved structure, the sequence identity between
mouse and yeast STIP1 is approximately 40% [1]. Thus, we characterized mouse STIP1
by NMR to facilitate future ligand studies. We confirmed the less than expected number
of observable STIP1 NMR amide resonances was not due to dimer formation of STIP1 or
the TPR2A domain, confirming a monomeric model of STPI1 in solution, which has
been challenged in previous studies [17, 18]. Rather, the lack of amide resonance signals
is likely reflective of STIP1’s large molecular weight (62.6 kDa) and predicted elongated
tertiary structure [15, 16]. Therefore, we assigned the amide proton resonances of the
structured domains of STIP1 (TPR1, TPR2A, TPR2B and DP2). Only a partial
assignment of DP1 could be obtained due to low signal strength (chapter 2).
The amide backbone resonance assignments lay the foundation for determining the
molecular details of PrPC (chapter 3) and S100A1 (chapter 4) complexes. These studies
can be extended to other STIP1 ligands, such as inhibitors of Hsp90 complex formation
with STIP1. Hsp90 client proteins include numerous oncogenic kinases, receptors and
transcription factors including Her2/neu, Bcr-Abl, vascular endothelial growth factor
(VEGF) and Raf-1 [19]. Inhibition of Hsp90 results in rapid proteasomal degradation of
these targets. Traditional Hsp90 inhibitors target the ATPase activity of Hsp90, which
have the undesired effect of Hsp70 induction resulting in resistance to apoptosis [20]. An
alternate approach has been proposed by Regan and co-workers, which targeted STIP1Hsp90 complexes, thus indirectly interrupting stabilization of oncogenic targets [21].
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Importantly, these small molecules demonstrated anti-tumorogenic effects without
inducing Hsp70 overexpression suggesting they may escape the positive feedback
mechanism of Hsp70 induction inherent to traditional Hsp90 ATPase inhibitors [22].

5.2

Mapping of AβO interface on PrP

PrPC is a high affinity receptor for AβO whose complex induces synaptic
dysfunction, inhibition of long term potentiation (LTP), loss of dendritic spines and,
ultimately, neuronal cell death [12, 23, 24]. AβO binding to PrPC is thought to be
mediated by two distinct regions in the disordered N-terminal of PrPC. These include a
highly basic cluster ‘KKRPK’ spanning residues 23-27 and residues 95-110 of PrPC [23,
25]. Our NMR studies of 15N-labelled PrP (90-231) titrated with preformed AβOs
revealed a short, highly localized region involved in AβO binding spanning residues 90110 of PrP. These results are consistent with the literature that implicates residues 95-110
in AβO binding [23, 25]. In addition, we noted small but notable chemical shift changes
of C-terminal residues of the globular domain of PrP. These may arise due to
conformational changes in PrP upon AβO or from transient contacts between PrP or AβO
species. No chemical shift changes or changes in peak intensity were noted for the Nterminal residues of PrP (23-95). High sequence redundancy and peak overlap prevented
the assignment of residues 23-95. Thus, we cannot rule out the possibility of minor, but
localized chemical shift changes in residues 23-95 upon AβO titration. However,
antibodies directed against residues 90-110 of PrP were sufficient to block AβO binding
to PrP, inhibit AβO neurotoxicity and improved cognitive deficits in AD transgenic
mouse models [24, 26, 27]. Thus, targeting residues of PrP 90-110 appears sufficient to
disrupt AβO induced deficits and may be a viable therapeutic approach in AD.
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5.3

Domains of STIP1 participating in PrP binding

The interaction between STIP1 with PrPC has been well documented to elicit
neuroprotective signaling in response to cellular stressors [6, 7, 11, 12]. Complex
formation has been suggested to be mediated between the TPR2A domain of STIP1 and
the disordered N-terminal of PrPC [6]. In the present study, we confirmed a high affinity
(1 x10-7 M Kd) complex between STIP1 and PrPC, while demonstrating that additional
domains of STPI1 are involved in binding. The structurally related TPR1 and TPR2A
domains, but not TPR2B, bound PrP. TPR1 and TPR2A binding were mutually
exclusive; suggesting binding of either domain to PrPC occludes the binding site of the
other. In addition, the DP1 domain was found to interact with the N-terminal (residues
23-95) of PrPC. This is the first reported instance of a binding partner for the DP1 domain
of STIP1.
The involvement of multiple domains of STIP1 in ligand binding is reminiscent of
STIP1 cochaperone interactions. Hsp70 binding to STIP1 is shared between the TPR1
and TPR2B domains and has functional consequences in for the proposed mechanism of
Hsp client transfer [3]. Upon Hsp90 recruitment, the high affinity Hsp70 site shifts from
TPR1 to TPR2B to presumably to spatially orient the client protein for efficient transfer
to Hsp90 at the TPR2A site [3]. Due to the modular structure of STIP1 and structural
homology of individual TPR domains, multi-domain STIP1 ligand interactions may be a
common feature of STIP1 complexes [1].
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5.4

Domains of STIP1 that inhibit PrP-AβO toxicity

We have previously demonstrated ectopic STIP1 treatment is capable of efficiently
inhibit Aβ oligomer toxicity in a PrPC dependent manner [12]. The identification of novel
domains participating in PrP complex formation led us to investigate the regions of
STIP1 responsible for its neuroprotection from AβO insult. Surface plasmon resonance
(SPR) was utilized to assess AβO binding to PrP (23-231) and the influence of STIP1 and
its individual domains in vitro. Our findings indicated that TPR1 and TPR2A domain of
STIP1, but not DP1, could inhibit AβO binding in a concentration dependant manner.
While DP1 may not directly participate in STPI1 inhibition of AβO binding, it likely
contributes to the greater binding affinity of STIP1 for PrP compared to the individual
domains alone. Considering TPR1 and TPR2A bind residues 90-231 of PrP, they may
physically occlude or induce conformational changes in PrP that inhibit AβO binding.
STIP1 binding to PrP has been suggested to induce significant conformational changes in
PrP [16]. Importantly, inhibition of AβO binding to PrP by TPR1 and TPR2A translated
to primary mouse hippocamapal neurons and rescued them from AβO induced cell death.
STIP1-PrPC induces Ca2+ influx resulting in downstream neuroprotective signaling
events through the alpha 7 nicotinic acetylcholine receptor (α7nAchR) [10]. Therefore,
we cannot rule out that TPR1 and TPR2A inhibition of AβO neuronal cell death is not
due to activation of a neuroprotective signaling cascade. Indeed, genetic deletion of
α7nAChR resulted in enhanced memory deficits and AβO accumulation in young 5month old APP transgenic mice [28]. Alternatively, STIP1 induced neuroprotective
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signaling events and direct inhibition of AβO binding to PrPC may act in concert to
protect primary hippocampal neurons against AβO neurotoxicity.
STIP1 upregulation has been noted in APPswe/PS1dE9 mouse model of AD and in
AD-afflicted brain homogenates [12]. Additionally, decreased levels of STIP1 in
mammalian neurons or knockdown of STIP1 in C. elegans increases the toxicity of
amyloid peptides [29][12]. Thus, extracellular STIP1 may serve as an endogenous
protective mechanism against neurotoxic AβOs in early stages of AD.

5.5
Regions of TPR1 and TPR2A involved in PrP
binding
While previous studies have suggested residues 230-245 of STIP1 and 113-128 of
PrP are involved in complex formation, molecular details at the residue level were absent
[6, 16]. The high structural similarity of TPR1 and TPR2A and their competitive binding
to PrP led us to investigate if complementary interfaces on each domain are involved.
Similar interfaces have been described for TPR1 and TPR2A binding to the C-terminal of
Hsp70 and Hsp90, respectively, as they both utilize conserved carboxylate clamp
residues to coordinate the acidic Hsp C-terminal tail [1]. Interestingly, NMR studies
revealed TPR1 and TPR2A binding interfaces for PrP are significantly different. TPR1
residues spanning the C-terminal of α-helix 6 and the interconnecting loop region
connecting it to α-helix 7 showed significant chemical shift changes. In contrast, the
TPR2A binding interface extended diagonally across the concave TPR2A surface which
overlaps with the Hsp90 binding site [1].
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Hsp90 chaperone function is critical for assuring proper folding of client proteins,
solubilizing protein aggregates or facilitating their targeting for proteasomal degradation
[19]. Hsp70 and Hsp90 have been shown to block Aβ1-42 aggregation in vitro [30]. Hsp90
and other Hsps also promote Aβ clearance by the stimulation of phagocytosis in
microglia [32]. Thus, modulation of Hsp proteins has gained traction as a possible
therapeutic pathway in AD [33].
Given both Hsp90 and STIP1 are secreted through an exosomal non-canonical
pathway and the TPR2A domain is involved in both PrP and Hsp90 binding, we
investigated the influence of PrP on Hsp90 binding to STIP1 [34, 35]. Interestingly, PrPSTIP1 complex formation promoted Hsp90 binding, suggesting they form a ternary
complex at the cellular membrane. STIP1 binding may induce structural conformational
changes in PrP, which may in turn recruit Hsp90 [16]. Hsp90 has been localized to the
cellular membrane, thus PrP-STIP1-Hsp90 complexes may form on the cellular surface
and influence STIP1 signaling events [36].

5.6

Molecular details of STIP1 interaction with S100A1

S100A1 is a Ca2+-binding protein sensor that modulates protein-protein interactions in
the cell [14]. S100A1 along with S100B and S100A6 are overexpressed in AD and are
considered as disease biomarkers [37]. S100A1 has been found to interact with various
co-chaperones through TPR domain interactions [13, 38]. TPR domains are common
structural elements shared by many Hsp70 and Hsp90 co-chaperones as they coordinate
binding to the highly conserved C-terminal Hsp ‘EEVD’ motifs [39]. Thus, S100A1 and

142

other S100 family members may function as regulators of Hsp client refolding by
influencing which co-chaperones are involved.
We have shown that S100A1 dimer bound each of the single TPR domains of STIP1
with various affinities in a Ca2+-dependent manner. Interestingly, this differs from many
S100A1 binding partners, which bind symmetrically to each S100 monomer, although
asymmetric interactions have been described for other S100 family members [40, 41].
However; it is important to note many studies displaying symmetrical binding utilize
short peptide sequences. In the full-length proteins, additional structural elements of the
S100 ligand may occlude the binding pocket of the S100 proteins, preventing symmetric
binding to each S100 monomer.
Our NMR studies indicated each TPR domain (TPR1, TPR2A and TPR2B) bound
identical hydrophobic region composed of α-helices III of each S100 monomer. This
observation agrees with these interactions being Ca2+-dependant. In the absence of Ca2+,
this region is inaccessible as it blocked by helix IV of each S100A1 subunit [42]. Upon
Ca2+ binding, helices IV of each S100 monomer undergo a large conformational change
by rotating approximately 100° and exposing the hydrophobic interface.
Unfortunately, the S100A1 binding interface on each TPR could not be determined
due to line broadening likely due to the large molecular weight or intermediate exchange
rates of the complex. However, due to the concave nature of the S100A1 binding site and
each TPR domain, binding likely involves the N or C-terminal helices of each TPR
domain to minimize steric clashing [1, 42]. Further study is required to determine TPR
site for S100A1 binding.

143

S100A1 and STPI1 are both found in the cytoplasm as well as the extracellular space
[34, 43]. S100A1 may modulate STIP1 ligand interactions influencing critical cellular
processes such as protein folding or cell signaling events through Hsp proteins or PrPC,
respectively. Thus, S100A1 over-expression in AD may alter the processing of Aβ and
tau aggregates by STIP1 or regulate formation of neuroprotective complexes through
PrPC.

5.7

Future directions

Our results suggest a ternary complex may form between STIP1, PrP and Hsp90;
however, the details of the regions of PrP involved and the stoichiometry of the
interaction are unknown. Different length PrP constructs can be used to determine if
Hsp90 recognizes the globular C-terminal or N-terminal of PrP. The solid support assay
developed here can be used with PrP (90-231) to rule out Hsp90 binding to the Nterminal of PrP. As well, sedimentation equilibrium or gel filtration experiments of
STIP1-PrP-Hsp90 can be preformed to determine the stoichiometry of the complex, as
larger species will change the elution profile or the rate the protein sediments.
Our results suggest the formation of a STIP1-Hsp90-PrP ternary complex in vitro,
however; it is unclear if the complex occurs on the cell surface or its effect on STIP1
signaling. Endogenously expressed GPI-anchored PrPC may behave differently than when
immobilized on to the polystyrene surface used in our solid support assays.
Immunohistochemistry and confocal microscopy studies may reveal if the proteins
colocalize on the cellular surface or if they are internalized together in intracellular
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compartments. Co-immunoprecipitaton of isolated membrane fractions may also reveal if
ternary complexes occur in cell culture.
The significant global loss in signal intensity prevented the determination of the
S100A1 binding interface on the individual TPR domains of STIP1. This is potentially
due to the increased size of the complex in relation to the individual proteins alone. A
common strategy for signal enhancement involves deuteration of the protein samples.
Due to their large size, larger proteins experience slower tumbling and thus enhanced
relaxation and decay resulting in loss of signal. Deuteration removes most 1H protons
improving relaxation rates thus resulting in a greater signal strength and resolution.
Alternatively, cross-saturation experiments can be used to identify the TPR binding
interface and have been used for protein-protein complexes >50 kDa. This technique
relies on uniformly labeling the target protein for which the interface is to be determined
with 2H and 15N (TPR domain). The aliphatic proton resonances of the unlableled binding
partner (S100A1) is non-selectively irradiated and transferred to the target through cross
relaxation by protons located at the interface. Thus, only residues at the interface are
affected and can be identified.

5.8

Conclusions

The work presented provides novel molecular details regarding STIP1 complexes
implicated in AD. STIP1’s modular structure and inter-domain homology, implicate
extensive multi-domain interactions in PrP and S100A1 binding. Additional domain
interactions were found to influence STIP1 binding to PrP and influence PrPC dependant
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AβO neurotoxicity. As well, structural studies of STIP1-S100A1 provided molecular
insights into their complex formation.
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